Network meta-analysis

Constipation

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

114

Randomized trials

Treatments

66,970

Participants

3,860

Events

In plain language

Across 114 trials with 66,970 participants, 6 of 47 treatments had a clearly better result than placebo on constipation, 16 a clearly worse one, and for 25 the evidence could not tell them apart from placebo. The most favorable estimate was for Glimepiride: hazard ratio (from event counts) 0.06 (95% credible interval 0.00 to 0.61).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Glimepiride GLIMEPIRIDE	0.06 (0.00 to 0.61)	0.00 to 0.62	Better
Premixed insulin INS_PREMIX	0.08 (0.00 to 0.82)	0.00 to 0.83	Better
Rosiglitazone ROSIGLITAZONE	0.15 (0.00 to 2.54)	0.00 to 2.60	Unclear
Macupatide OTHER_ACTIVE_macupatide	0.18 (0.00 to 2.91)	0.00 to 2.99	Unclear
Standard care or no added treatment STANDARD_CARE	0.21 (0.04 to 0.80)	0.04 to 0.83	Better
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.23 (0.02 to 1.29)	0.02 to 1.34	Unclear
Liraglutide after insulin degludec injection LIRAGL_SC	0.25 (0.00 to 6.41)	0.00 to 6.40	Unclear
Insulin icodec INS_ICODEC	0.30 (0.09 to 0.98)	0.08 to 1.02	Better
Pioglitazone PIOGLITAZONE	0.34 (0.13 to 0.80)	0.11 to 0.88	Better
Insulin lispro (prandial) INS_LISPRO	0.44 (0.16 to 1.12)	0.15 to 1.20	Unclear
Insulin detemir INS_DETEMIR	0.45 (0.10 to 1.65)	0.10 to 1.78	Unclear
Insulin glargine INS_GLARGINE	0.48 (0.32 to 0.70)	0.27 to 0.84	Better
Metformin METFORMIN	0.52 (0.24 to 1.07)	0.22 to 1.17	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.52 (0.18 to 1.34)	0.17 to 1.45	Unclear
Insulin degludec INS_DEGLUDEC	0.55 (0.27 to 1.15)	0.25 to 1.29	Unclear
Dulaglutide with macupatide injection DULAMACU_SC	0.63 (0.05 to 4.78)	0.05 to 4.86	Unclear
Sitagliptin SITAGLIPTIN	0.71 (0.43 to 1.19)	0.38 to 1.35	Unclear
Insulin glargine with lixisenatide injection IGLARLIXI_SC	0.85 (0.28 to 2.50)	0.26 to 2.66	Unclear
Glibenclamide GLIBENCLAMIDE	1.11 (0.40 to 2.79)	0.38 to 2.95	Unclear
Insulin degludec with liraglutide injection IDEGLIRA_SC	1.28 (0.67 to 2.46)	0.61 to 2.75	Unclear
Ecnoglutide injection ECNO_SC	1.34 (0.33 to 8.30)	0.31 to 8.73	Unclear
Ecc500 po ECC500_PO	1.37 (0.40 to 5.91)	0.37 to 6.17	Unclear
Insulin icodec with semaglutide injection ICOSEMA_SC	1.50 (0.61 to 3.56)	0.56 to 3.81	Unclear
Lixisenatide injection LIXI_SC	1.57 (1.03 to 2.49)	0.89 to 2.85	Worse
Exenatide extended release injection EXENER_SC	1.61 (1.12 to 2.34)	0.94 to 2.77	Worse
Exenatide injection EXEN_SC	1.76 (1.23 to 2.58)	1.04 to 3.06	Worse
Dulaglutide injection DULA_SC	1.85 (1.47 to 2.38)	1.19 to 3.01	Worse
Liraglutide injection LIRA_SC	1.89 (1.48 to 2.46)	1.20 to 3.01	Worse
Canagliflozin CANAGLIFLOZIN	1.91 (0.93 to 3.83)	0.83 to 4.15	Unclear
Efsubaglutide alfa injection EFSUBA_SC	1.94 (0.49 to 8.69)	0.47 to 8.93	Unclear
Dapagliflozin DAPAGLIFLOZIN	2.00 (0.25 to 24.43)	0.23 to 26.03	Unclear
Albiglutide injection ALBI_SC	2.02 (1.14 to 3.71)	1.03 to 4.14	Worse
Efpe sc EFPE_SC	2.25 (0.96 to 5.93)	0.87 to 6.31	Unclear
Semaglutide tablet SEMA_PO	2.29 (1.69 to 3.18)	1.40 to 3.84	Worse
Semaglutide injection SEMA_SC	2.40 (1.83 to 3.29)	1.51 to 4.06	Worse
Exenatide and rosiglitazone injection EXENROSI_SC	2.66 (0.42 to 18.47)	0.40 to 18.70	Unclear
Safiglipron (HRS-7535) tablet SAFIGL_PO	2.69 (0.38 to 30.88)	0.36 to 31.28	Unclear
Cotadutide injection COTA_SC	3.12 (1.28 to 8.78)	1.15 to 9.33	Worse
Tirzepatide injection TIRZ_SC	3.16 (2.10 to 4.94)	1.80 to 5.76	Worse
Retatrutide injection RETA_SC	3.23 (1.17 to 10.81)	1.07 to 11.16	Worse
Orforglipron tablet ORFO_PO	3.43 (2.52 to 4.81)	2.12 to 5.75	Worse
Vildagliptin VILDAGLIPTIN	3.52 (0.54 to 30.14)	0.52 to 30.08	Unclear
Taspoglutide injection TASP_SC	3.66 (1.86 to 7.46)	1.67 to 8.32	Worse
Liraglutide plus canagliflozin injection CANALIRA_SC	3.85 (1.01 to 15.00)	0.95 to 15.87	Worse
Insulin aspart (prandial) INS_ASPART	4.43 (0.18 to 140)	0.18 to 146	Unclear
Loti po LOTI_PO	4.93 (2.48 to 10.76)	2.24 to 11.74	Worse
Exenimp implant EXENIMP_IMPLANT	5.46 (1.00 to 47.37)	0.96 to 47.96	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	GLIMEPIRIDE	INS_PREMIX	ROSIGLITAZONE	OTHER_ACTIVE_macupatide	STANDARD_CARE	OTHER_ACTIVE_sulfonylurea	LIRAGL_SC	INS_ICODEC	PIOGLITAZONE	INS_LISPRO	INS_DETEMIR	INS_GLARGINE	METFORMIN	OTHER_ACTIVE_additional_OAD	INS_DEGLUDEC	DULAMACU_SC	SITAGLIPTIN	IGLARLIXI_SC	GLIBENCLAMIDE	IDEGLIRA_SC	ECNO_SC	ECC500_PO	ICOSEMA_SC	LIXI_SC	EXENER_SC	EXEN_SC	DULA_SC	LIRA_SC	CANAGLIFLOZIN	EFSUBA_SC	DAPAGLIFLOZIN	ALBI_SC	EFPE_SC	SEMA_PO	SEMA_SC	EXENROSI_SC	SAFIGL_PO	COTA_SC	TIRZ_SC	RETA_SC	ORFO_PO	VILDAGLIPTIN	TASP_SC	CANALIRA_SC	INS_ASPART	LOTI_PO	EXENIMP_IMPLANT
PLACEBO	PLACEBO	15.39 1.65 to 502	13.13 1.22 to 485	6.55 0.39 to 308	5.44 0.34 to 310	4.74 1.25 to 26.33	4.27 0.77 to 44.98	3.94 0.16 to 257	3.37 1.02 to 11.32	2.94 1.24 to 7.99	2.25 0.90 to 6.25	2.22 0.61 to 10.08	2.08 1.43 to 3.08	1.92 0.94 to 4.18	1.92 0.74 to 5.65	1.80 0.87 to 3.77	1.59 0.21 to 19.63	1.40 0.84 to 2.32	1.17 0.40 to 3.59	0.90 0.36 to 2.49	0.78 0.41 to 1.48	0.74 0.12 to 3.05	0.73 0.17 to 2.52	0.67 0.28 to 1.63	0.64 0.40 to 0.97	0.62 0.43 to 0.89	0.57 0.39 to 0.81	0.54 0.42 to 0.68	0.53 0.41 to 0.68	0.52 0.26 to 1.07	0.51 0.12 to 2.02	0.50 0.04 to 3.95	0.49 0.27 to 0.87	0.45 0.17 to 1.04	0.44 0.31 to 0.59	0.42 0.30 to 0.55	0.38 0.05 to 2.40	0.37 0.03 to 2.65	0.32 0.11 to 0.78	0.32 0.20 to 0.48	0.31 0.09 to 0.85	0.29 0.21 to 0.40	0.28 0.03 to 1.86	0.27 0.13 to 0.54	0.26 0.07 to 0.99	0.23 0.01 to 5.54	0.20 0.09 to 0.40	0.18 0.02 to 1.00
GLIMEPIRIDE	0.06 0.00 to 0.61	GLIMEPIRIDE	0.84 0.01 to 54.87	0.41 0.00 to 37.01	0.35 0.00 to 34.75	0.31 0.01 to 5.14	0.28 0.01 to 6.57	0.25 0.00 to 29.09	0.21 0.01 to 2.82	0.19 0.01 to 2.16	0.15 0.00 to 1.82	0.14 0.00 to 2.10	0.14 0.00 to 1.30	0.13 0.00 to 1.38	0.12 0.00 to 1.61	0.12 0.00 to 1.25	0.10 0.00 to 2.85	0.09 0.00 to 0.90	0.08 0.00 to 0.91	0.06 0.00 to 0.69	0.05 0.00 to 0.52	0.04 0.00 to 0.69	0.04 0.00 to 0.67	0.04 0.00 to 0.50	0.04 0.00 to 0.40	0.04 0.00 to 0.38	0.04 0.00 to 0.35	0.04 0.00 to 0.33	0.03 0.00 to 0.33	0.03 0.00 to 0.36	0.03 0.00 to 0.48	0.03 0.00 to 0.76	0.03 0.00 to 0.33	0.03 0.00 to 0.31	0.03 0.00 to 0.27	0.03 0.00 to 0.25	0.02 0.00 to 0.45	0.02 0.00 to 0.49	0.02 0.00 to 0.23	0.02 0.00 to 0.19	0.02 0.00 to 0.23	0.02 0.00 to 0.18	0.02 0.00 to 0.37	0.02 0.00 to 0.19	0.02 0.00 to 0.23	0.01 0.00 to 0.70	0.01 0.00 to 0.14	0.01 0.00 to 0.21
INS_PREMIX	0.08 0.00 to 0.82	1.19 0.02 to 87.99	INS_PREMIX	0.49 0.01 to 43.49	0.42 0.00 to 47.48	0.37 0.01 to 6.72	0.33 0.01 to 9.32	0.30 0.00 to 37.35	0.25 0.01 to 3.72	0.23 0.01 to 2.77	0.17 0.00 to 2.23	0.17 0.00 to 2.88	0.16 0.00 to 1.74	0.15 0.00 to 1.79	0.15 0.00 to 2.05	0.14 0.00 to 1.60	0.12 0.00 to 3.76	0.11 0.00 to 1.20	0.09 0.00 to 1.17	0.07 0.00 to 0.93	0.06 0.00 to 0.67	0.05 0.00 to 0.91	0.05 0.00 to 0.83	0.05 0.00 to 0.65	0.05 0.00 to 0.53	0.05 0.00 to 0.50	0.04 0.00 to 0.45	0.04 0.00 to 0.44	0.04 0.00 to 0.43	0.04 0.00 to 0.47	0.04 0.00 to 0.62	0.04 0.00 to 0.96	0.04 0.00 to 0.43	0.03 0.00 to 0.45	0.03 0.00 to 0.36	0.03 0.00 to 0.34	0.03 0.00 to 0.56	0.03 0.00 to 0.65	0.02 0.00 to 0.30	0.02 0.00 to 0.26	0.02 0.00 to 0.33	0.02 0.00 to 0.25	0.02 0.00 to 0.44	0.02 0.00 to 0.24	0.02 0.00 to 0.30	0.02 0.00 to 0.96	0.02 0.00 to 0.19	0.01 0.00 to 0.27
ROSIGLITAZONE	0.15 0.00 to 2.54	2.44 0.03 to 219	2.03 0.02 to 180	ROSIGLITAZONE	0.80 0.01 to 99.99	0.71 0.01 to 20.76	0.65 0.01 to 27.16	0.59 0.00 to 97.92	0.51 0.01 to 10.88	0.46 0.01 to 8.99	0.35 0.01 to 6.84	0.33 0.01 to 8.47	0.32 0.01 to 5.40	0.29 0.01 to 5.47	0.30 0.01 to 6.05	0.28 0.01 to 5.07	0.24 0.00 to 11.16	0.21 0.00 to 3.77	0.18 0.00 to 3.58	0.14 0.00 to 2.71	0.12 0.00 to 2.18	0.11 0.00 to 2.72	0.10 0.00 to 2.56	0.10 0.00 to 1.96	0.10 0.00 to 1.63	0.09 0.00 to 1.63	0.09 0.00 to 1.42	0.08 0.00 to 1.36	0.08 0.00 to 1.34	0.08 0.00 to 1.45	0.08 0.00 to 1.87	0.07 0.00 to 2.64	0.07 0.00 to 1.36	0.07 0.00 to 1.31	0.07 0.00 to 1.12	0.06 0.00 to 1.06	0.06 0.00 to 1.00	0.05 0.00 to 1.80	0.05 0.00 to 0.97	0.05 0.00 to 0.81	0.05 0.00 to 0.95	0.04 0.00 to 0.75	0.04 0.00 to 1.33	0.04 0.00 to 0.74	0.04 0.00 to 0.91	0.03 0.00 to 2.48	0.03 0.00 to 0.56	0.03 0.00 to 0.77
OTHER_ACTIVE_macupatide	0.18 0.00 to 2.91	2.84 0.03 to 265	2.41 0.02 to 211	1.25 0.01 to 159	OTHER_ACTIVE_macupatide	0.86 0.01 to 21.07	0.78 0.01 to 29.65	0.75 0.00 to 107	0.61 0.01 to 13.14	0.54 0.01 to 10.43	0.42 0.01 to 7.92	0.40 0.01 to 9.56	0.38 0.01 to 6.12	0.36 0.01 to 6.32	0.35 0.01 to 7.00	0.33 0.01 to 5.71	0.30 0.00 to 10.24	0.26 0.00 to 4.22	0.21 0.00 to 4.42	0.16 0.00 to 3.23	0.14 0.00 to 2.40	0.13 0.00 to 3.00	0.13 0.00 to 2.80	0.12 0.00 to 2.23	0.12 0.00 to 1.94	0.11 0.00 to 1.86	0.10 0.00 to 1.67	0.10 0.00 to 1.53	0.10 0.00 to 1.51	0.10 0.00 to 1.62	0.09 0.00 to 2.14	0.08 0.00 to 3.18	0.09 0.00 to 1.51	0.08 0.00 to 1.54	0.08 0.00 to 1.27	0.08 0.00 to 1.22	0.07 0.00 to 2.06	0.06 0.00 to 2.21	0.06 0.00 to 1.08	0.06 0.00 to 0.93	0.05 0.00 to 1.10	0.05 0.00 to 0.86	0.05 0.00 to 1.41	0.05 0.00 to 0.84	0.05 0.00 to 1.09	0.04 0.00 to 2.84	0.04 0.00 to 0.64	0.03 0.00 to 0.86
STANDARD_CARE	0.21 0.04 to 0.80	3.20 0.19 to 123	2.73 0.15 to 138	1.41 0.05 to 74.75	1.16 0.05 to 70.27	STANDARD_CARE	0.90 0.08 to 13.90	0.82 0.02 to 69.86	0.69 0.09 to 4.30	0.62 0.10 to 3.38	0.48 0.07 to 2.54	0.47 0.06 to 3.38	0.44 0.08 to 1.72	0.40 0.07 to 1.81	0.41 0.06 to 2.22	0.38 0.06 to 1.68	0.33 0.02 to 5.38	0.30 0.05 to 1.19	0.25 0.03 to 1.42	0.19 0.03 to 0.98	0.16 0.03 to 0.69	0.15 0.01 to 1.10	0.15 0.02 to 0.95	0.14 0.02 to 0.69	0.14 0.02 to 0.55	0.13 0.02 to 0.51	0.12 0.02 to 0.46	0.11 0.02 to 0.43	0.11 0.02 to 0.41	0.11 0.02 to 0.50	0.11 0.01 to 0.71	0.10 0.01 to 1.20	0.10 0.02 to 0.42	0.09 0.01 to 0.46	0.09 0.02 to 0.35	0.09 0.02 to 0.34	0.08 0.01 to 0.77	0.08 0.00 to 0.80	0.07 0.01 to 0.32	0.07 0.01 to 0.27	0.06 0.01 to 0.36	0.06 0.01 to 0.24	0.06 0.00 to 0.56	0.06 0.01 to 0.26	0.05 0.01 to 0.35	0.05 0.00 to 1.51	0.04 0.01 to 0.19	0.04 0.00 to 0.34
OTHER_ACTIVE_sulfonylurea	0.23 0.02 to 1.29	3.60 0.15 to 164	3.05 0.11 to 162	1.53 0.04 to 102	1.28 0.03 to 101	1.11 0.07 to 12.49	OTHER_ACTIVE_sulfonylurea	0.91 0.02 to 78.36	0.77 0.06 to 6.31	0.70 0.06 to 5.15	0.53 0.04 to 3.77	0.51 0.04 to 4.82	0.50 0.04 to 2.79	0.46 0.04 to 2.85	0.45 0.04 to 3.50	0.42 0.03 to 2.71	0.37 0.02 to 7.99	0.33 0.03 to 1.92	0.28 0.02 to 2.09	0.21 0.02 to 1.48	0.18 0.02 to 1.09	0.17 0.01 to 1.59	0.16 0.01 to 1.42	0.16 0.01 to 1.08	0.15 0.01 to 0.86	0.15 0.01 to 0.82	0.13 0.01 to 0.74	0.13 0.01 to 0.72	0.12 0.01 to 0.67	0.12 0.01 to 0.77	0.12 0.01 to 1.11	0.11 0.00 to 1.79	0.11 0.01 to 0.69	0.10 0.01 to 0.71	0.10 0.01 to 0.58	0.10 0.01 to 0.55	0.09 0.00 to 1.06	0.08 0.00 to 1.25	0.07 0.01 to 0.52	0.07 0.01 to 0.42	0.07 0.01 to 0.53	0.07 0.01 to 0.39	0.06 0.00 to 0.86	0.06 0.01 to 0.40	0.06 0.00 to 0.55	0.05 0.00 to 1.86	0.05 0.00 to 0.30	0.04 0.00 to 0.49
LIRAGL_SC	0.25 0.00 to 6.41	4.01 0.03 to 426	3.32 0.03 to 400	1.69 0.01 to 254	1.34 0.01 to 203	1.22 0.01 to 45.76	1.10 0.01 to 59.89	LIRAGL_SC	0.84 0.01 to 25.87	0.75 0.01 to 21.82	0.57 0.01 to 17.50	0.56 0.01 to 21.27	0.53 0.01 to 13.13	0.48 0.01 to 13.03	0.47 0.01 to 16.44	0.46 0.01 to 12.71	0.40 0.00 to 22.38	0.35 0.01 to 9.45	0.30 0.00 to 8.98	0.23 0.00 to 6.66	0.20 0.00 to 5.23	0.18 0.00 to 6.39	0.18 0.00 to 6.01	0.17 0.00 to 4.86	0.16 0.00 to 4.32	0.16 0.00 to 4.03	0.14 0.00 to 3.72	0.14 0.00 to 3.47	0.13 0.00 to 3.39	0.13 0.00 to 3.64	0.12 0.00 to 4.66	0.11 0.00 to 7.13	0.12 0.00 to 3.39	0.11 0.00 to 3.20	0.11 0.00 to 2.77	0.10 0.00 to 2.74	0.09 0.00 to 4.17	0.08 0.00 to 4.67	0.08 0.00 to 2.28	0.08 0.00 to 2.03	0.08 0.00 to 2.22	0.07 0.00 to 1.88	0.07 0.00 to 3.35	0.07 0.00 to 1.95	0.06 0.00 to 2.27	0.05 0.00 to 5.69	0.05 0.00 to 1.47	0.04 0.00 to 1.82
INS_ICODEC	0.30 0.09 to 0.98	4.73 0.35 to 176	4.07 0.27 to 174	1.97 0.09 to 108	1.65 0.08 to 107	1.45 0.23 to 11.18	1.30 0.16 to 17.71	1.19 0.04 to 88.66	INS_ICODEC	0.89 0.21 to 4.05	0.68 0.15 to 3.22	0.66 0.12 to 4.37	0.62 0.18 to 2.21	0.57 0.15 to 2.33	0.58 0.13 to 2.68	0.53 0.13 to 2.13	0.48 0.05 to 7.36	0.42 0.11 to 1.52	0.35 0.07 to 1.76	0.27 0.06 to 1.27	0.23 0.06 to 0.88	0.22 0.03 to 1.44	0.22 0.03 to 1.25	0.20 0.08 to 0.44	0.19 0.05 to 0.66	0.19 0.05 to 0.63	0.17 0.05 to 0.60	0.16 0.05 to 0.54	0.16 0.05 to 0.52	0.16 0.04 to 0.58	0.15 0.02 to 0.95	0.15 0.01 to 1.65	0.15 0.04 to 0.55	0.13 0.03 to 0.61	0.13 0.04 to 0.44	0.12 0.04 to 0.39	0.11 0.01 to 0.99	0.11 0.01 to 1.09	0.09 0.02 to 0.43	0.09 0.03 to 0.33	0.09 0.02 to 0.45	0.09 0.02 to 0.30	0.08 0.01 to 0.74	0.08 0.02 to 0.32	0.08 0.01 to 0.44	0.07 0.00 to 1.85	0.06 0.01 to 0.24	0.05 0.00 to 0.45
PIOGLITAZONE	0.34 0.13 to 0.80	5.18 0.46 to 177	4.39 0.36 to 172	2.16 0.11 to 111	1.84 0.10 to 112	1.61 0.30 to 10.51	1.44 0.19 to 17.28	1.33 0.05 to 97.80	1.12 0.25 to 4.82	PIOGLITAZONE	0.76 0.20 to 2.93	0.75 0.15 to 4.13	0.71 0.25 to 1.75	0.65 0.21 to 1.83	0.64 0.17 to 2.56	0.61 0.18 to 1.90	0.53 0.06 to 7.15	0.47 0.17 to 1.17	0.40 0.09 to 1.59	0.30 0.08 to 1.15	0.26 0.08 to 0.76	0.25 0.03 to 1.34	0.24 0.04 to 1.12	0.22 0.06 to 0.75	0.21 0.07 to 0.55	0.21 0.08 to 0.48	0.19 0.07 to 0.46	0.18 0.07 to 0.43	0.18 0.07 to 0.42	0.18 0.05 to 0.55	0.17 0.03 to 0.89	0.17 0.01 to 1.62	0.17 0.05 to 0.46	0.15 0.04 to 0.52	0.15 0.05 to 0.37	0.14 0.05 to 0.34	0.12 0.01 to 0.97	0.13 0.01 to 1.10	0.11 0.03 to 0.37	0.11 0.04 to 0.27	0.10 0.02 to 0.40	0.10 0.04 to 0.24	0.09 0.01 to 0.76	0.09 0.03 to 0.26	0.09 0.02 to 0.45	0.08 0.00 to 1.89	0.07 0.02 to 0.21	0.06 0.01 to 0.39
INS_LISPRO	0.44 0.16 to 1.12	6.75 0.55 to 238	5.75 0.45 to 229	2.87 0.15 to 146	2.40 0.13 to 158	2.10 0.39 to 15.04	1.87 0.27 to 24.27	1.74 0.06 to 121	1.47 0.31 to 6.65	1.31 0.34 to 5.09	INS_LISPRO	0.97 0.19 to 5.82	0.93 0.31 to 2.42	0.86 0.25 to 2.87	0.86 0.21 to 3.42	0.80 0.23 to 2.58	0.70 0.07 to 10.07	0.62 0.20 to 1.75	0.52 0.12 to 2.14	0.40 0.10 to 1.56	0.34 0.10 to 1.06	0.32 0.04 to 1.70	0.32 0.05 to 1.57	0.29 0.08 to 1.03	0.28 0.09 to 0.75	0.28 0.09 to 0.72	0.25 0.09 to 0.64	0.24 0.08 to 0.61	0.24 0.08 to 0.60	0.23 0.07 to 0.73	0.22 0.04 to 1.22	0.22 0.01 to 2.23	0.22 0.07 to 0.64	0.19 0.05 to 0.71	0.19 0.07 to 0.52	0.18 0.06 to 0.47	0.17 0.02 to 1.25	0.16 0.01 to 1.46	0.14 0.03 to 0.52	0.14 0.05 to 0.33	0.13 0.03 to 0.55	0.13 0.04 to 0.34	0.12 0.01 to 1.05	0.12 0.04 to 0.37	0.11 0.02 to 0.58	0.10 0.00 to 2.51	0.09 0.03 to 0.28	0.08 0.01 to 0.54
INS_DETEMIR	0.45 0.10 to 1.65	7.01 0.48 to 266	5.92 0.35 to 253	3.01 0.12 to 163	2.52 0.10 to 166	2.14 0.30 to 17.28	1.95 0.21 to 27.25	1.78 0.05 to 141	1.52 0.23 to 8.65	1.34 0.24 to 6.49	1.03 0.17 to 5.24	INS_DETEMIR	0.95 0.20 to 3.53	0.87 0.17 to 3.75	0.87 0.15 to 4.65	0.81 0.16 to 3.65	0.72 0.06 to 11.53	0.64 0.14 to 2.39	0.54 0.08 to 2.96	0.41 0.07 to 2.10	0.35 0.07 to 1.48	0.33 0.03 to 2.38	0.32 0.04 to 2.13	0.30 0.05 to 1.45	0.29 0.06 to 1.13	0.28 0.07 to 0.97	0.26 0.06 to 0.95	0.24 0.05 to 0.91	0.24 0.05 to 0.88	0.24 0.05 to 1.05	0.23 0.03 to 1.56	0.22 0.01 to 2.74	0.22 0.04 to 0.93	0.20 0.03 to 0.95	0.20 0.04 to 0.73	0.19 0.04 to 0.69	0.17 0.02 to 1.55	0.16 0.01 to 1.84	0.14 0.02 to 0.71	0.14 0.03 to 0.53	0.14 0.02 to 0.75	0.13 0.03 to 0.50	0.12 0.01 to 1.25	0.12 0.02 to 0.51	0.12 0.02 to 0.77	0.10 0.00 to 2.88	0.09 0.02 to 0.41	0.08 0.01 to 0.69
INS_GLARGINE	0.48 0.32 to 0.70	7.36 0.77 to 242	6.33 0.58 to 244	3.11 0.19 to 156	2.61 0.16 to 148	2.27 0.58 to 12.82	2.01 0.36 to 23.49	1.90 0.08 to 120	1.62 0.45 to 5.64	1.41 0.57 to 3.93	1.08 0.41 to 3.18	1.05 0.28 to 4.98	INS_GLARGINE	0.92 0.43 to 2.08	0.92 0.33 to 2.81	0.87 0.39 to 1.96	0.76 0.10 to 9.51	0.67 0.36 to 1.21	0.56 0.19 to 1.75	0.43 0.17 to 1.27	0.37 0.18 to 0.78	0.36 0.06 to 1.52	0.35 0.08 to 1.26	0.32 0.13 to 0.82	0.31 0.17 to 0.52	0.30 0.19 to 0.46	0.27 0.17 to 0.44	0.26 0.17 to 0.38	0.25 0.17 to 0.38	0.25 0.12 to 0.55	0.25 0.05 to 1.02	0.24 0.02 to 2.00	0.24 0.12 to 0.44	0.21 0.07 to 0.55	0.21 0.13 to 0.34	0.20 0.13 to 0.30	0.18 0.03 to 1.17	0.18 0.01 to 1.31	0.15 0.05 to 0.40	0.15 0.09 to 0.24	0.15 0.04 to 0.43	0.14 0.08 to 0.23	0.14 0.02 to 0.93	0.13 0.06 to 0.29	0.12 0.03 to 0.50	0.11 0.00 to 2.54	0.10 0.04 to 0.21	0.09 0.01 to 0.50
METFORMIN	0.52 0.24 to 1.07	7.84 0.72 to 266	6.77 0.56 to 256	3.39 0.18 to 171	2.81 0.16 to 165	2.47 0.55 to 14.43	2.17 0.35 to 25.19	2.08 0.08 to 133	1.75 0.43 to 6.89	1.53 0.55 to 4.68	1.17 0.35 to 4.08	1.15 0.27 to 5.86	1.08 0.48 to 2.34	METFORMIN	1.00 0.30 to 3.65	0.93 0.33 to 2.55	0.84 0.10 to 10.39	0.73 0.32 to 1.58	0.61 0.17 to 2.18	0.47 0.14 to 1.60	0.41 0.15 to 1.03	0.38 0.05 to 1.85	0.38 0.07 to 1.60	0.34 0.11 to 1.06	0.33 0.14 to 0.74	0.32 0.15 to 0.64	0.29 0.13 to 0.63	0.28 0.13 to 0.57	0.28 0.13 to 0.57	0.27 0.10 to 0.75	0.27 0.05 to 1.26	0.26 0.02 to 2.44	0.26 0.10 to 0.63	0.23 0.07 to 0.71	0.23 0.10 to 0.49	0.22 0.10 to 0.45	0.19 0.02 to 1.39	0.19 0.01 to 1.60	0.17 0.05 to 0.52	0.16 0.07 to 0.37	0.16 0.04 to 0.55	0.15 0.07 to 0.32	0.14 0.02 to 1.12	0.14 0.05 to 0.36	0.13 0.03 to 0.60	0.12 0.00 to 2.93	0.10 0.04 to 0.29	0.09 0.01 to 0.61
OTHER_ACTIVE_additional_OAD	0.52 0.18 to 1.34	8.06 0.62 to 303	6.77 0.49 to 266	3.38 0.17 to 171	2.86 0.14 to 171	2.46 0.45 to 17.38	2.21 0.29 to 28.35	2.11 0.06 to 147	1.73 0.37 to 7.60	1.56 0.39 to 5.97	1.16 0.29 to 4.74	1.14 0.21 to 6.63	1.09 0.36 to 3.01	1.00 0.27 to 3.32	OTHER_ACTIVE_additional_OAD	0.93 0.25 to 3.16	0.82 0.08 to 11.21	0.73 0.23 to 2.08	0.61 0.13 to 2.63	0.48 0.11 to 1.85	0.41 0.12 to 1.27	0.38 0.05 to 2.09	0.37 0.06 to 1.84	0.35 0.09 to 1.19	0.33 0.10 to 0.94	0.32 0.11 to 0.88	0.30 0.09 to 0.81	0.28 0.09 to 0.73	0.28 0.09 to 0.73	0.27 0.08 to 0.83	0.26 0.04 to 1.43	0.25 0.02 to 2.56	0.26 0.08 to 0.76	0.23 0.05 to 0.87	0.22 0.07 to 0.62	0.22 0.08 to 0.53	0.19 0.02 to 1.55	0.19 0.01 to 1.72	0.16 0.04 to 0.62	0.17 0.05 to 0.45	0.16 0.03 to 0.66	0.15 0.05 to 0.41	0.14 0.01 to 1.20	0.14 0.04 to 0.46	0.13 0.02 to 0.68	0.12 0.00 to 2.96	0.10 0.03 to 0.35	0.09 0.01 to 0.62
INS_DEGLUDEC	0.55 0.27 to 1.15	8.51 0.80 to 301	7.30 0.62 to 283	3.63 0.20 to 186	3.00 0.18 to 180	2.63 0.60 to 16.16	2.37 0.37 to 29.20	2.18 0.08 to 158	1.87 0.47 to 7.55	1.65 0.53 to 5.44	1.24 0.39 to 4.43	1.23 0.27 to 6.37	1.15 0.51 to 2.56	1.07 0.39 to 3.04	1.07 0.32 to 3.95	INS_DEGLUDEC	0.88 0.11 to 11.36	0.78 0.33 to 1.78	0.66 0.18 to 2.40	0.50 0.16 to 1.66	0.43 0.22 to 0.82	0.41 0.06 to 2.12	0.40 0.08 to 1.68	0.37 0.12 to 1.15	0.35 0.15 to 0.82	0.34 0.16 to 0.75	0.31 0.14 to 0.70	0.30 0.14 to 0.64	0.29 0.15 to 0.58	0.29 0.11 to 0.80	0.28 0.06 to 1.36	0.27 0.02 to 2.64	0.27 0.11 to 0.66	0.25 0.08 to 0.76	0.24 0.11 to 0.53	0.23 0.10 to 0.49	0.21 0.03 to 1.56	0.21 0.02 to 1.63	0.18 0.05 to 0.56	0.18 0.08 to 0.41	0.17 0.04 to 0.60	0.16 0.07 to 0.35	0.16 0.02 to 1.16	0.15 0.06 to 0.41	0.15 0.03 to 0.64	0.13 0.00 to 3.14	0.11 0.04 to 0.30	0.10 0.01 to 0.63
DULAMACU_SC	0.63 0.05 to 4.78	9.75 0.35 to 513	8.31 0.27 to 475	4.23 0.09 to 336	3.37 0.10 to 266	3.02 0.19 to 42.49	2.72 0.13 to 58.59	2.50 0.04 to 271	2.08 0.14 to 22.04	1.89 0.14 to 17.00	1.43 0.10 to 13.51	1.40 0.09 to 16.04	1.32 0.11 to 9.86	1.19 0.10 to 10.29	1.22 0.09 to 12.06	1.13 0.09 to 9.14	DULAMACU_SC	0.88 0.07 to 7.04	0.74 0.05 to 7.69	0.58 0.04 to 5.39	0.49 0.04 to 3.99	0.44 0.02 to 5.50	0.44 0.03 to 5.16	0.42 0.03 to 3.82	0.40 0.03 to 3.16	0.39 0.03 to 2.92	0.36 0.03 to 2.81	0.34 0.03 to 2.51	0.33 0.03 to 2.49	0.33 0.03 to 2.77	0.31 0.02 to 3.75	0.30 0.01 to 5.76	0.31 0.02 to 2.46	0.27 0.02 to 2.47	0.27 0.02 to 2.10	0.26 0.02 to 1.98	0.23 0.01 to 3.86	0.22 0.01 to 3.90	0.20 0.01 to 1.78	0.20 0.02 to 1.51	0.19 0.01 to 1.89	0.18 0.01 to 1.40	0.17 0.01 to 2.60	0.17 0.01 to 1.47	0.16 0.01 to 1.79	0.14 0.00 to 5.60	0.13 0.01 to 1.05	0.11 0.00 to 1.67
SITAGLIPTIN	0.71 0.43 to 1.19	10.90 1.11 to 368	9.21 0.83 to 348	4.66 0.27 to 218	3.89 0.24 to 224	3.37 0.84 to 19.49	3.04 0.52 to 33.46	2.85 0.11 to 193	2.40 0.66 to 8.80	2.11 0.86 to 5.86	1.61 0.57 to 5.02	1.57 0.42 to 7.34	1.49 0.82 to 2.75	1.37 0.63 to 3.12	1.37 0.48 to 4.28	1.29 0.56 to 3.02	1.14 0.14 to 13.96	SITAGLIPTIN	0.85 0.26 to 2.74	0.65 0.23 to 1.96	0.55 0.26 to 1.19	0.53 0.08 to 2.33	0.52 0.11 to 1.99	0.48 0.18 to 1.31	0.46 0.24 to 0.85	0.45 0.26 to 0.73	0.40 0.23 to 0.70	0.39 0.23 to 0.65	0.38 0.23 to 0.62	0.38 0.16 to 0.86	0.37 0.08 to 1.58	0.36 0.03 to 3.04	0.35 0.16 to 0.71	0.32 0.11 to 0.85	0.31 0.17 to 0.55	0.30 0.17 to 0.50	0.27 0.04 to 1.75	0.26 0.02 to 1.97	0.23 0.08 to 0.62	0.23 0.12 to 0.42	0.22 0.06 to 0.69	0.21 0.11 to 0.37	0.20 0.02 to 1.42	0.19 0.09 to 0.41	0.19 0.04 to 0.75	0.16 0.01 to 3.96	0.15 0.06 to 0.34	0.13 0.01 to 0.76
IGLARLIXI_SC	0.85 0.28 to 2.50	13.26 1.10 to 494	11.30 0.86 to 453	5.64 0.28 to 294	4.68 0.23 to 299	4.07 0.70 to 29.89	3.60 0.48 to 45.98	3.37 0.11 to 254	2.83 0.57 to 14.26	2.52 0.63 to 10.88	1.91 0.47 to 8.32	1.87 0.34 to 12.21	1.77 0.57 to 5.37	1.64 0.46 to 6.01	1.65 0.38 to 7.58	1.52 0.42 to 5.48	1.36 0.13 to 18.83	1.18 0.37 to 3.84	IGLARLIXI_SC	0.78 0.18 to 3.17	0.66 0.19 to 2.29	0.62 0.08 to 3.80	0.61 0.10 to 3.24	0.56 0.14 to 2.23	0.54 0.19 to 1.49	0.52 0.17 to 1.59	0.48 0.15 to 1.47	0.46 0.15 to 1.38	0.45 0.15 to 1.35	0.44 0.12 to 1.66	0.43 0.07 to 2.48	0.42 0.03 to 4.37	0.42 0.12 to 1.39	0.38 0.09 to 1.46	0.37 0.12 to 1.12	0.35 0.11 to 1.06	0.32 0.03 to 2.72	0.31 0.02 to 2.94	0.27 0.06 to 1.10	0.27 0.08 to 0.85	0.25 0.05 to 1.16	0.25 0.08 to 0.74	0.24 0.02 to 2.11	0.23 0.06 to 0.81	0.22 0.04 to 1.22	0.19 0.01 to 5.24	0.17 0.04 to 0.61	0.15 0.01 to 1.15
GLIBENCLAMIDE	1.11 0.40 to 2.79	16.88 1.46 to 591	14.51 1.07 to 626	7.19 0.37 to 389	6.08 0.31 to 363	5.25 1.02 to 35.28	4.72 0.68 to 56.84	4.42 0.15 to 294	3.67 0.79 to 16.89	3.28 0.87 to 12.54	2.49 0.64 to 10.02	2.44 0.48 to 14.14	2.31 0.79 to 5.95	2.12 0.63 to 7.14	2.10 0.54 to 8.77	2.00 0.60 to 6.20	1.73 0.19 to 23.81	1.54 0.51 to 4.28	1.29 0.32 to 5.50	GLIBENCLAMIDE	0.86 0.27 to 2.52	0.81 0.10 to 4.39	0.79 0.14 to 3.80	0.73 0.20 to 2.60	0.70 0.24 to 1.92	0.69 0.24 to 1.80	0.63 0.22 to 1.67	0.60 0.21 to 1.51	0.59 0.22 to 1.42	0.57 0.17 to 1.82	0.56 0.10 to 2.89	0.54 0.04 to 5.62	0.54 0.17 to 1.55	0.48 0.13 to 1.75	0.48 0.17 to 1.28	0.46 0.16 to 1.17	0.42 0.05 to 3.25	0.40 0.03 to 3.73	0.35 0.09 to 1.23	0.35 0.12 to 0.94	0.33 0.07 to 1.35	0.32 0.11 to 0.86	0.30 0.03 to 2.59	0.30 0.09 to 0.96	0.28 0.06 to 1.44	0.25 0.01 to 6.38	0.22 0.06 to 0.70	0.20 0.02 to 1.41
IDEGLIRA_SC	1.28 0.67 to 2.46	19.88 1.91 to 669	16.78 1.48 to 677	8.41 0.46 to 416	7.01 0.42 to 413	6.10 1.45 to 36.36	5.43 0.91 to 63.87	5.05 0.19 to 341	4.34 1.14 to 17.01	3.82 1.32 to 12.11	2.93 0.94 to 9.53	2.85 0.68 to 14.53	2.68 1.28 to 5.58	2.46 0.97 to 6.53	2.47 0.79 to 8.60	2.31 1.21 to 4.48	2.05 0.25 to 26.53	1.80 0.84 to 3.89	1.51 0.44 to 5.40	1.16 0.40 to 3.75	IDEGLIRA_SC	0.94 0.14 to 4.64	0.94 0.19 to 3.73	0.86 0.30 to 2.56	0.82 0.38 to 1.75	0.80 0.40 to 1.65	0.73 0.35 to 1.53	0.69 0.36 to 1.35	0.68 0.37 to 1.26	0.67 0.27 to 1.77	0.66 0.13 to 3.02	0.64 0.05 to 5.90	0.64 0.27 to 1.40	0.57 0.18 to 1.69	0.56 0.28 to 1.12	0.54 0.27 to 1.05	0.48 0.06 to 3.49	0.48 0.04 to 3.76	0.41 0.13 to 1.20	0.41 0.19 to 0.86	0.40 0.11 to 1.33	0.37 0.18 to 0.75	0.36 0.04 to 2.63	0.35 0.14 to 0.90	0.33 0.08 to 1.46	0.29 0.01 to 7.21	0.26 0.10 to 0.68	0.23 0.02 to 1.44
ECNO_SC	1.34 0.33 to 8.30	22.26 1.45 to 982	18.90 1.10 to 967	9.48 0.37 to 633	7.88 0.33 to 554	6.63 0.91 to 73.04	6.06 0.63 to 114	5.62 0.16 to 454	4.61 0.70 to 38.68	4.08 0.75 to 30.79	3.08 0.59 to 23.41	3.05 0.42 to 30.82	2.81 0.66 to 17.99	2.63 0.54 to 18.55	2.66 0.48 to 20.22	2.42 0.47 to 17.23	2.26 0.18 to 43.42	1.89 0.43 to 12.30	1.60 0.26 to 13.27	1.23 0.23 to 9.68	1.06 0.22 to 6.93	ECNO_SC	0.98 0.13 to 8.40	0.91 0.17 to 6.68	0.85 0.19 to 5.69	0.83 0.20 to 5.29	0.76 0.18 to 4.82	0.73 0.17 to 4.59	0.71 0.17 to 4.45	0.71 0.14 to 5.02	0.70 0.09 to 6.51	0.69 0.04 to 10.29	0.67 0.14 to 4.44	0.60 0.11 to 4.15	0.59 0.14 to 3.57	0.56 0.13 to 3.51	0.52 0.05 to 6.20	0.51 0.03 to 6.85	0.43 0.07 to 3.13	0.43 0.10 to 2.78	0.41 0.06 to 3.06	0.39 0.09 to 2.44	0.39 0.03 to 4.65	0.37 0.08 to 2.46	0.36 0.05 to 3.24	0.31 0.01 to 10.73	0.27 0.05 to 1.86	0.25 0.02 to 2.62
ECC500_PO	1.37 0.40 to 5.91	22.62 1.50 to 971	18.50 1.20 to 874	9.55 0.39 to 549	7.87 0.36 to 525	6.67 1.05 to 56.83	6.06 0.70 to 91.27	5.63 0.17 to 437	4.62 0.80 to 30.31	4.09 0.89 to 24.22	3.15 0.64 to 18.25	3.11 0.47 to 25.18	2.85 0.79 to 13.15	2.65 0.63 to 13.74	2.68 0.54 to 15.86	2.49 0.60 to 12.36	2.28 0.19 to 36.37	1.92 0.50 to 8.88	1.64 0.31 to 9.89	1.26 0.26 to 7.08	1.07 0.27 to 5.23	1.02 0.12 to 7.74	ECC500_PO	0.92 0.20 to 4.98	0.87 0.23 to 3.96	0.85 0.24 to 3.84	0.77 0.21 to 3.51	0.73 0.21 to 3.25	0.73 0.21 to 3.13	0.72 0.17 to 3.63	0.70 0.10 to 5.16	0.71 0.04 to 8.29	0.68 0.17 to 3.27	0.61 0.13 to 3.26	0.60 0.17 to 2.63	0.57 0.16 to 2.47	0.53 0.05 to 5.12	0.52 0.03 to 5.49	0.44 0.09 to 2.50	0.43 0.12 to 1.98	0.42 0.07 to 2.48	0.40 0.11 to 1.75	0.38 0.03 to 4.29	0.37 0.09 to 1.88	0.35 0.05 to 2.64	0.31 0.01 to 9.38	0.28 0.06 to 1.36	0.25 0.02 to 2.43
ICOSEMA_SC	1.50 0.61 to 3.56	23.36 1.99 to 801	20.03 1.55 to 794	9.91 0.51 to 487	8.15 0.45 to 496	7.19 1.44 to 47.37	6.42 0.92 to 78.19	5.93 0.21 to 403	4.96 2.27 to 11.81	4.49 1.33 to 16.26	3.43 0.97 to 12.87	3.35 0.69 to 18.53	3.13 1.22 to 7.99	2.91 0.95 to 9.12	2.90 0.84 to 10.87	2.72 0.87 to 8.22	2.38 0.26 to 32.40	2.08 0.76 to 5.68	1.78 0.45 to 7.29	1.36 0.38 to 5.11	1.17 0.39 to 3.38	1.10 0.15 to 5.89	1.09 0.20 to 5.08	ICOSEMA_SC	0.96 0.35 to 2.48	0.93 0.36 to 2.29	0.85 0.32 to 2.14	0.81 0.33 to 1.95	0.79 0.32 to 1.93	0.79 0.27 to 2.22	0.77 0.14 to 3.99	0.76 0.05 to 7.29	0.74 0.26 to 2.02	0.65 0.18 to 2.33	0.66 0.25 to 1.64	0.62 0.26 to 1.41	0.57 0.07 to 4.22	0.56 0.04 to 4.76	0.47 0.12 to 1.69	0.47 0.18 to 1.23	0.46 0.11 to 1.72	0.44 0.17 to 1.09	0.42 0.04 to 3.27	0.41 0.13 to 1.25	0.38 0.08 to 1.91	0.34 0.01 to 8.62	0.30 0.10 to 0.92	0.27 0.03 to 1.90
LIXI_SC	1.57 1.03 to 2.49	24.00 2.49 to 810	20.36 1.90 to 770	10.33 0.61 to 496	8.62 0.52 to 498	7.39 1.83 to 42.63	6.67 1.17 to 74.74	6.25 0.23 to 425	5.26 1.52 to 19.39	4.67 1.81 to 13.46	3.53 1.33 to 10.61	3.44 0.88 to 16.78	3.27 1.91 to 5.81	3.03 1.35 to 7.18	3.00 1.07 to 9.86	2.84 1.22 to 6.67	2.50 0.32 to 30.95	2.19 1.18 to 4.21	1.84 0.67 to 5.36	1.43 0.52 to 4.22	1.22 0.57 to 2.65	1.18 0.18 to 5.13	1.15 0.25 to 4.36	1.05 0.40 to 2.88	LIXI_SC	0.97 0.58 to 1.69	0.89 0.54 to 1.48	0.85 0.52 to 1.39	0.83 0.52 to 1.37	0.82 0.37 to 1.91	0.81 0.17 to 3.41	0.80 0.06 to 6.54	0.77 0.37 to 1.59	0.70 0.24 to 1.82	0.69 0.40 to 1.18	0.65 0.39 to 1.10	0.60 0.08 to 3.84	0.58 0.05 to 4.35	0.50 0.17 to 1.37	0.49 0.28 to 0.90	0.48 0.14 to 1.49	0.46 0.27 to 0.79	0.44 0.05 to 3.07	0.43 0.20 to 0.93	0.41 0.10 to 1.65	0.36 0.01 to 8.50	0.32 0.13 to 0.72	0.29 0.03 to 1.64
EXENER_SC	1.61 1.12 to 2.34	24.59 2.65 to 800	20.88 2.01 to 829	10.60 0.61 to 515	8.82 0.54 to 508	7.61 1.96 to 43.03	6.81 1.21 to 75.84	6.35 0.25 to 419	5.39 1.60 to 18.64	4.72 2.09 to 12.64	3.62 1.38 to 10.71	3.53 1.03 to 15.38	3.35 2.17 to 5.23	3.08 1.55 to 6.67	3.08 1.14 to 9.52	2.90 1.34 to 6.45	2.57 0.34 to 30.86	2.24 1.37 to 3.78	1.91 0.63 to 5.97	1.46 0.56 to 4.22	1.25 0.61 to 2.52	1.20 0.19 to 5.11	1.18 0.26 to 4.24	1.08 0.44 to 2.77	1.03 0.59 to 1.73	EXENER_SC	0.91 0.59 to 1.38	0.87 0.59 to 1.29	0.85 0.58 to 1.24	0.84 0.40 to 1.81	0.82 0.18 to 3.45	0.81 0.07 to 6.83	0.80 0.41 to 1.49	0.71 0.26 to 1.79	0.70 0.44 to 1.11	0.67 0.44 to 0.99	0.61 0.09 to 3.85	0.60 0.05 to 4.55	0.52 0.17 to 1.34	0.51 0.30 to 0.85	0.49 0.14 to 1.43	0.47 0.29 to 0.75	0.45 0.05 to 3.14	0.44 0.21 to 0.90	0.41 0.11 to 1.60	0.37 0.01 to 8.74	0.33 0.13 to 0.72	0.30 0.03 to 1.60
EXEN_SC	1.76 1.23 to 2.58	26.88 2.89 to 879	23.02 2.21 to 876	11.58 0.70 to 565	9.61 0.60 to 548	8.33 2.15 to 48.95	7.58 1.35 to 83.51	7.01 0.27 to 448	5.97 1.68 to 20.80	5.20 2.18 to 14.26	3.99 1.57 to 11.29	3.89 1.05 to 17.89	3.68 2.28 to 6.06	3.41 1.59 to 7.80	3.38 1.23 to 10.66	3.19 1.43 to 7.31	2.79 0.36 to 34.46	2.47 1.42 to 4.37	2.09 0.68 to 6.47	1.60 0.60 to 4.57	1.37 0.65 to 2.86	1.32 0.21 to 5.67	1.30 0.28 to 4.71	1.17 0.47 to 3.09	1.13 0.68 to 1.84	1.09 0.72 to 1.69	EXEN_SC	0.95 0.63 to 1.43	0.93 0.62 to 1.42	0.92 0.43 to 2.10	0.90 0.20 to 3.84	0.89 0.07 to 7.49	0.87 0.44 to 1.69	0.79 0.27 to 1.97	0.77 0.48 to 1.24	0.73 0.47 to 1.13	0.67 0.10 to 4.14	0.66 0.05 to 5.00	0.57 0.20 to 1.48	0.56 0.33 to 0.94	0.55 0.16 to 1.62	0.51 0.31 to 0.83	0.50 0.06 to 3.45	0.48 0.26 to 0.90	0.46 0.11 to 1.85	0.40 0.01 to 9.41	0.36 0.15 to 0.79	0.33 0.04 to 1.69
DULA_SC	1.85 1.47 to 2.38	28.36 3.07 to 944	24.52 2.27 to 896	12.08 0.73 to 587	9.85 0.65 to 595	8.71 2.31 to 48.42	7.87 1.39 to 82.95	7.32 0.29 to 479	6.21 1.85 to 21.49	5.45 2.31 to 14.98	4.17 1.64 to 11.77	4.09 1.10 to 18.54	3.85 2.67 to 5.72	3.56 1.76 to 7.70	3.56 1.37 to 10.77	3.35 1.57 to 7.12	2.92 0.40 to 35.78	2.59 1.53 to 4.43	2.19 0.72 to 6.69	1.67 0.66 to 4.67	1.44 0.74 to 2.80	1.38 0.22 to 5.72	1.36 0.31 to 4.76	1.23 0.51 to 3.05	1.18 0.72 to 1.91	1.15 0.77 to 1.71	1.05 0.70 to 1.58	DULA_SC	0.98 0.73 to 1.34	0.97 0.48 to 2.04	0.95 0.21 to 3.82	0.92 0.08 to 7.71	0.92 0.49 to 1.66	0.82 0.31 to 2.01	0.81 0.56 to 1.17	0.77 0.55 to 1.05	0.70 0.10 to 4.41	0.69 0.06 to 4.94	0.59 0.21 to 1.47	0.59 0.38 to 0.89	0.57 0.17 to 1.56	0.54 0.37 to 0.78	0.52 0.06 to 3.48	0.51 0.24 to 1.04	0.48 0.12 to 1.84	0.42 0.01 to 10.37	0.38 0.17 to 0.76	0.34 0.04 to 1.84
LIRA_SC	1.89 1.48 to 2.46	29.06 3.06 to 964	24.52 2.30 to 939	12.28 0.75 to 593	10.23 0.66 to 610	8.90 2.43 to 49.07	8.03 1.50 to 85.06	7.42 0.29 to 499	6.34 1.93 to 21.66	5.56 2.37 to 15.06	4.24 1.65 to 12.02	4.15 1.14 to 18.79	3.93 2.63 to 5.98	3.62 1.75 to 7.92	3.61 1.37 to 10.97	3.40 1.71 to 6.88	3.01 0.40 to 37.51	2.63 1.61 to 4.39	2.23 0.74 to 6.75	1.70 0.71 to 4.62	1.47 0.80 to 2.69	1.41 0.22 to 5.86	1.38 0.32 to 4.87	1.26 0.52 to 3.15	1.21 0.73 to 1.94	1.17 0.81 to 1.71	1.07 0.70 to 1.61	1.02 0.75 to 1.38	LIRA_SC	0.99 0.49 to 2.05	0.97 0.22 to 3.90	0.95 0.08 to 8.04	0.94 0.51 to 1.62	0.84 0.31 to 2.07	0.83 0.58 to 1.18	0.79 0.55 to 1.08	0.71 0.10 to 4.52	0.70 0.06 to 5.09	0.61 0.22 to 1.48	0.60 0.37 to 0.95	0.58 0.17 to 1.65	0.55 0.37 to 0.81	0.53 0.06 to 3.58	0.51 0.25 to 1.05	0.49 0.13 to 1.86	0.43 0.01 to 10.39	0.38 0.17 to 0.80	0.35 0.04 to 1.89
CANAGLIFLOZIN	1.91 0.93 to 3.83	29.19 2.81 to 955	25.04 2.12 to 960	12.52 0.69 to 614	10.40 0.62 to 596	9.03 1.99 to 57.12	8.16 1.29 to 97.99	7.63 0.27 to 505	6.39 1.72 to 25.03	5.69 1.83 to 18.33	4.31 1.37 to 14.99	4.22 0.95 to 21.49	4.00 1.81 to 8.38	3.70 1.33 to 10.02	3.66 1.20 to 12.62	3.43 1.25 to 9.39	3.07 0.36 to 39.12	2.66 1.17 to 6.18	2.27 0.60 to 8.39	1.74 0.55 to 5.72	1.50 0.57 to 3.76	1.40 0.20 to 7.11	1.38 0.28 to 5.74	1.26 0.45 to 3.72	1.21 0.52 to 2.72	1.19 0.55 to 2.51	1.09 0.48 to 2.32	1.03 0.49 to 2.08	1.01 0.49 to 2.06	CANAGLIFLOZIN	0.97 0.19 to 4.60	0.96 0.07 to 8.76	0.95 0.37 to 2.28	0.84 0.26 to 2.51	0.84 0.38 to 1.79	0.79 0.39 to 1.53	0.73 0.10 to 5.05	0.71 0.06 to 5.63	0.60 0.18 to 1.89	0.61 0.26 to 1.32	0.58 0.14 to 2.03	0.56 0.25 to 1.18	0.53 0.06 to 3.96	0.52 0.19 to 1.36	0.49 0.13 to 1.90	0.43 0.01 to 10.76	0.39 0.13 to 1.02	0.35 0.04 to 2.18
EFSUBA_SC	1.94 0.49 to 8.69	31.18 2.08 to 1359	26.19 1.63 to 1218	13.30 0.53 to 785	10.98 0.47 to 746	9.41 1.40 to 85.31	8.62 0.90 to 132	8.20 0.21 to 618	6.56 1.05 to 42.57	5.83 1.13 to 33.68	4.48 0.82 to 26.86	4.36 0.64 to 36.04	4.06 0.98 to 19.21	3.77 0.79 to 20.16	3.81 0.70 to 22.52	3.51 0.73 to 17.88	3.18 0.27 to 53.40	2.73 0.63 to 12.93	2.34 0.40 to 14.25	1.77 0.35 to 10.29	1.52 0.33 to 7.60	1.42 0.15 to 11.40	1.43 0.19 to 10.42	1.29 0.25 to 7.25	1.24 0.29 to 5.76	1.22 0.29 to 5.53	1.11 0.26 to 5.02	1.05 0.26 to 4.75	1.03 0.26 to 4.59	1.03 0.22 to 5.33	EFSUBA_SC	0.96 0.06 to 12.68	0.96 0.22 to 4.66	0.87 0.16 to 4.65	0.85 0.21 to 3.85	0.81 0.20 to 3.62	0.75 0.07 to 8.05	0.71 0.04 to 8.56	0.62 0.11 to 3.46	0.62 0.15 to 2.86	0.59 0.10 to 3.74	0.57 0.14 to 2.56	0.55 0.05 to 6.25	0.54 0.11 to 2.63	0.51 0.07 to 3.75	0.44 0.01 to 14.66	0.39 0.08 to 1.98	0.35 0.03 to 3.34
DAPAGLIFLOZIN	2.00 0.25 to 24.43	33.43 1.32 to 2242	27.85 1.04 to 1861	14.47 0.38 to 1344	11.83 0.31 to 1218	9.79 0.83 to 183	9.13 0.56 to 258	8.88 0.14 to 952	6.69 0.61 to 107	5.95 0.62 to 88.76	4.57 0.45 to 69.19	4.56 0.36 to 84.82	4.15 0.50 to 53.56	3.87 0.41 to 54.52	3.96 0.39 to 59.48	3.65 0.38 to 48.32	3.35 0.17 to 101	2.80 0.33 to 35.74	2.41 0.23 to 36.15	1.84 0.18 to 25.34	1.57 0.17 to 20.69	1.45 0.10 to 27.25	1.40 0.12 to 23.58	1.32 0.14 to 19.45	1.26 0.15 to 16.69	1.23 0.15 to 15.36	1.12 0.13 to 14.43	1.08 0.13 to 13.27	1.05 0.12 to 13.28	1.04 0.11 to 14.37	1.04 0.08 to 17.27	DAPAGLIFLOZIN	0.98 0.11 to 12.74	0.87 0.09 to 12.20	0.88 0.10 to 10.99	0.83 0.10 to 10.13	0.78 0.04 to 16.13	0.74 0.29 to 1.71	0.65 0.06 to 8.41	0.63 0.07 to 8.08	0.61 0.06 to 9.52	0.59 0.07 to 7.12	0.56 0.03 to 12.93	0.55 0.06 to 7.27	0.51 0.04 to 9.04	0.45 0.01 to 25.31	0.40 0.04 to 5.47	0.37 0.02 to 7.62
ALBI_SC	2.02 1.14 to 3.71	31.24 3.05 to 1068	26.70 2.30 to 1067	13.42 0.74 to 647	11.23 0.66 to 676	9.60 2.38 to 57.52	8.74 1.46 to 98.33	8.24 0.29 to 563	6.85 1.82 to 25.36	5.99 2.18 to 19.12	4.56 1.57 to 14.89	4.48 1.08 to 22.63	4.23 2.29 to 8.13	3.91 1.58 to 10.26	3.92 1.32 to 13.32	3.64 1.52 to 9.39	3.22 0.41 to 43.81	2.82 1.40 to 6.07	2.40 0.72 to 8.29	1.84 0.64 to 5.75	1.56 0.72 to 3.66	1.49 0.23 to 7.03	1.47 0.31 to 5.98	1.35 0.49 to 3.89	1.29 0.63 to 2.70	1.25 0.67 to 2.47	1.15 0.59 to 2.27	1.09 0.60 to 2.05	1.07 0.62 to 1.95	1.06 0.44 to 2.74	1.04 0.21 to 4.58	1.02 0.08 to 8.81	ALBI_SC	0.90 0.30 to 2.55	0.88 0.47 to 1.73	0.84 0.46 to 1.61	0.77 0.10 to 5.29	0.77 0.06 to 5.66	0.65 0.21 to 1.88	0.64 0.32 to 1.32	0.62 0.17 to 2.07	0.59 0.31 to 1.15	0.57 0.06 to 4.13	0.55 0.23 to 1.34	0.53 0.12 to 2.25	0.46 0.01 to 11.62	0.41 0.16 to 1.03	0.37 0.04 to 2.28
EFPE_SC	2.25 0.96 to 5.93	35.58 3.26 to 1376	30.08 2.24 to 1186	15.22 0.76 to 810	12.43 0.65 to 765	10.86 2.16 to 74.78	9.63 1.40 to 122	9.14 0.31 to 680	7.68 1.65 to 34.86	6.72 1.93 to 26.46	5.16 1.40 to 20.41	5.01 1.05 to 29.48	4.71 1.83 to 13.36	4.37 1.41 to 15.19	4.37 1.15 to 18.55	4.07 1.32 to 13.24	3.64 0.40 to 50.91	3.16 1.17 to 9.20	2.66 0.69 to 11.59	2.08 0.57 to 8.00	1.75 0.59 to 5.56	1.67 0.24 to 9.35	1.65 0.31 to 7.68	1.53 0.43 to 5.54	1.42 0.55 to 4.09	1.40 0.56 to 3.90	1.27 0.51 to 3.67	1.21 0.50 to 3.22	1.19 0.48 to 3.22	1.18 0.40 to 3.80	1.16 0.21 to 6.20	1.15 0.08 to 11.14	1.11 0.39 to 3.36	EFPE_SC	0.98 0.40 to 2.73	0.94 0.37 to 2.52	0.86 0.10 to 6.86	0.84 0.06 to 7.41	0.71 0.19 to 2.70	0.71 0.27 to 1.99	0.69 0.16 to 2.92	0.65 0.26 to 1.83	0.64 0.07 to 5.32	0.61 0.21 to 2.06	0.58 0.11 to 3.08	0.51 0.01 to 13.35	0.46 0.15 to 1.50	0.41 0.04 to 3.01
SEMA_PO	2.29 1.69 to 3.18	35.06 3.72 to 1164	30.02 2.78 to 1139	15.10 0.89 to 749	12.42 0.79 to 736	10.81 2.83 to 62.13	9.72 1.72 to 108	9.08 0.36 to 627	7.73 2.26 to 26.97	6.77 2.73 to 19.30	5.21 1.94 to 14.85	5.09 1.37 to 23.68	4.76 2.97 to 7.78	4.43 2.05 to 9.93	4.45 1.61 to 13.76	4.15 1.90 to 9.12	3.64 0.48 to 43.71	3.21 1.82 to 5.72	2.71 0.89 to 8.44	2.07 0.78 to 5.85	1.78 0.89 to 3.60	1.70 0.28 to 7.11	1.67 0.38 to 5.94	1.52 0.61 to 3.94	1.46 0.85 to 2.49	1.43 0.90 to 2.29	1.30 0.81 to 2.06	1.24 0.86 to 1.78	1.21 0.85 to 1.74	1.20 0.56 to 2.64	1.18 0.26 to 4.79	1.14 0.09 to 9.55	1.13 0.58 to 2.13	1.02 0.37 to 2.52	SEMA_PO	0.95 0.63 to 1.43	0.87 0.12 to 5.55	0.85 0.07 to 6.28	0.74 0.26 to 1.90	0.73 0.43 to 1.21	0.71 0.21 to 2.05	0.67 0.47 to 0.94	0.65 0.07 to 4.37	0.62 0.29 to 1.31	0.59 0.15 to 2.37	0.52 0.02 to 12.29	0.47 0.21 to 0.94	0.42 0.05 to 2.38
SEMA_SC	2.40 1.83 to 3.29	36.89 4.01 to 1221	31.47 2.93 to 1186	15.72 0.95 to 755	13.01 0.82 to 728	11.40 2.98 to 63.46	10.23 1.81 to 111	9.61 0.36 to 620	8.11 2.56 to 26.96	7.13 2.95 to 19.32	5.43 2.13 to 15.66	5.33 1.46 to 23.68	4.98 3.30 to 7.83	4.63 2.23 to 10.21	4.60 1.89 to 13.22	4.33 2.03 to 9.67	3.84 0.51 to 46.93	3.35 2.02 to 5.77	2.84 0.94 to 8.90	2.17 0.85 to 6.16	1.86 0.96 to 3.74	1.78 0.28 to 7.58	1.77 0.41 to 6.27	1.61 0.71 to 3.78	1.53 0.91 to 2.55	1.49 1.01 to 2.26	1.36 0.89 to 2.13	1.30 0.95 to 1.81	1.27 0.92 to 1.81	1.26 0.65 to 2.55	1.23 0.28 to 4.99	1.21 0.10 to 10.08	1.19 0.62 to 2.18	1.06 0.40 to 2.69	1.05 0.70 to 1.60	SEMA_SC	0.91 0.13 to 5.90	0.89 0.08 to 6.52	0.77 0.27 to 1.95	0.76 0.47 to 1.22	0.74 0.22 to 2.09	0.70 0.46 to 1.08	0.68 0.08 to 4.69	0.65 0.31 to 1.37	0.62 0.16 to 2.42	0.55 0.02 to 12.93	0.49 0.22 to 1.04	0.44 0.05 to 2.48
EXENROSI_SC	2.66 0.42 to 18.47	41.61 2.22 to 2292	36.01 1.79 to 2190	17.35 1.00 to 1032	15.17 0.49 to 1180	12.85 1.31 to 162	11.59 0.94 to 246	10.97 0.24 to 910	8.89 1.01 to 84.11	8.03 1.03 to 66.83	6.06 0.80 to 51.60	5.97 0.65 to 64.24	5.55 0.85 to 39.42	5.16 0.72 to 41.32	5.17 0.64 to 44.45	4.78 0.64 to 38.63	4.35 0.26 to 94.82	3.71 0.57 to 27.44	3.11 0.37 to 28.72	2.40 0.31 to 20.77	2.06 0.29 to 15.84	1.92 0.16 to 21.03	1.90 0.20 to 19.04	1.76 0.24 to 14.32	1.68 0.26 to 11.95	1.64 0.26 to 11.70	1.50 0.24 to 10.19	1.43 0.23 to 9.95	1.40 0.22 to 9.75	1.38 0.20 to 10.49	1.33 0.12 to 14.54	1.29 0.06 to 22.98	1.30 0.19 to 9.94	1.17 0.15 to 9.68	1.15 0.18 to 8.13	1.10 0.17 to 7.79	EXENROSI_SC	0.94 0.05 to 16.07	0.84 0.10 to 6.94	0.84 0.12 to 5.97	0.81 0.09 to 7.07	0.77 0.12 to 5.57	0.75 0.05 to 10.94	0.72 0.11 to 5.30	0.69 0.07 to 6.90	0.59 0.01 to 23.23	0.53 0.07 to 4.24	0.48 0.03 to 6.10
SAFIGL_PO	2.69 0.38 to 30.88	44.41 2.04 to 2810	37.72 1.54 to 2438	19.41 0.55 to 1646	16.15 0.45 to 1585	13.32 1.25 to 240	12.27 0.80 to 345	12.08 0.21 to 1215	9.01 0.92 to 143	7.95 0.91 to 112	6.20 0.68 to 86.28	6.14 0.54 to 105	5.55 0.77 to 67.55	5.20 0.62 to 67.44	5.32 0.58 to 74.56	4.87 0.61 to 61.65	4.47 0.26 to 129	3.81 0.51 to 45.86	3.20 0.34 to 45.33	2.52 0.27 to 33.05	2.10 0.27 to 26.17	1.94 0.15 to 35.39	1.92 0.18 to 29.47	1.79 0.21 to 25.33	1.71 0.23 to 21.03	1.67 0.22 to 19.69	1.52 0.20 to 18.34	1.45 0.20 to 16.87	1.43 0.20 to 16.35	1.41 0.18 to 17.56	1.41 0.12 to 23.03	1.35 0.58 to 3.42	1.30 0.18 to 16.50	1.19 0.13 to 15.73	1.18 0.16 to 13.37	1.12 0.15 to 12.91	1.06 0.06 to 19.79	SAFIGL_PO	0.86 0.09 to 10.74	0.85 0.11 to 10.33	0.82 0.08 to 12.06	0.79 0.11 to 8.96	0.75 0.04 to 16.95	0.74 0.09 to 9.08	0.70 0.07 to 11.85	0.62 0.01 to 35.49	0.54 0.07 to 6.85	0.50 0.03 to 9.65
COTA_SC	3.12 1.28 to 8.78	49.84 4.29 to 1707	41.70 3.37 to 1779	20.85 1.03 to 1075	17.55 0.92 to 1083	15.02 3.09 to 105	13.68 1.91 to 166	12.60 0.44 to 918	10.69 2.35 to 52.00	9.36 2.68 to 37.60	7.14 1.93 to 30.42	7.03 1.40 to 42.68	6.51 2.48 to 19.13	6.05 1.93 to 21.84	6.07 1.61 to 26.75	5.66 1.78 to 19.73	5.02 0.56 to 69.54	4.38 1.62 to 13.31	3.75 0.91 to 16.22	2.85 0.81 to 11.72	2.42 0.83 to 7.94	2.32 0.32 to 13.39	2.30 0.40 to 11.29	2.11 0.59 to 8.05	1.99 0.73 to 5.98	1.94 0.74 to 5.73	1.76 0.67 to 5.08	1.68 0.68 to 4.79	1.65 0.68 to 4.55	1.66 0.53 to 5.63	1.62 0.29 to 8.74	1.54 0.12 to 16.94	1.54 0.53 to 4.76	1.40 0.37 to 5.23	1.35 0.53 to 3.89	1.30 0.51 to 3.70	1.19 0.14 to 9.61	1.16 0.09 to 11.47	COTA_SC	1.00 0.36 to 3.03	0.97 0.21 to 3.99	0.91 0.35 to 2.66	0.88 0.09 to 7.45	0.85 0.27 to 2.93	0.81 0.16 to 4.25	0.73 0.02 to 18.89	0.63 0.19 to 2.14	0.58 0.06 to 4.29
TIRZ_SC	3.16 2.10 to 4.94	48.87 5.17 to 1588	41.46 3.78 to 1618	20.52 1.24 to 1025	17.11 1.08 to 999	15.09 3.75 to 87.69	13.36 2.38 to 150	12.63 0.49 to 829	10.53 2.99 to 37.34	9.40 3.66 to 26.62	7.12 3.03 to 19.66	7.02 1.87 to 33.08	6.58 4.13 to 10.77	6.11 2.71 to 14.17	6.06 2.23 to 19.08	5.68 2.45 to 13.20	5.00 0.66 to 60.80	4.43 2.38 to 8.47	3.74 1.18 to 12.22	2.87 1.07 to 8.52	2.46 1.16 to 5.30	2.35 0.36 to 10.17	2.32 0.50 to 8.54	2.11 0.81 to 5.55	2.03 1.11 to 3.62	1.96 1.17 to 3.34	1.79 1.06 to 3.07	1.71 1.12 to 2.66	1.68 1.05 to 2.69	1.64 0.76 to 3.80	1.62 0.35 to 6.83	1.58 0.12 to 13.67	1.57 0.76 to 3.09	1.41 0.50 to 3.71	1.37 0.83 to 2.34	1.32 0.82 to 2.13	1.20 0.17 to 8.07	1.17 0.10 to 8.86	1.00 0.33 to 2.77	TIRZ_SC	0.97 0.28 to 2.90	0.92 0.54 to 1.56	0.89 0.10 to 6.25	0.87 0.39 to 1.92	0.82 0.20 to 3.36	0.74 0.02 to 17.69	0.64 0.27 to 1.46	0.58 0.06 to 3.26
RETA_SC	3.23 1.17 to 10.81	51.94 4.29 to 2006	44.01 3.04 to 1794	21.99 1.05 to 1177	18.55 0.91 to 1141	15.79 2.80 to 115	14.30 1.88 to 193	13.27 0.45 to 1038	10.99 2.22 to 56.02	9.68 2.47 to 45.48	7.46 1.82 to 35.90	7.25 1.34 to 51.01	6.81 2.34 to 23.36	6.35 1.83 to 24.43	6.36 1.52 to 29.96	5.87 1.66 to 23.59	5.23 0.53 to 74.68	4.54 1.44 to 16.26	3.94 0.86 to 18.58	2.99 0.74 to 13.70	2.53 0.75 to 9.52	2.42 0.33 to 15.83	2.37 0.40 to 13.69	2.18 0.58 to 9.30	2.07 0.67 to 7.40	2.02 0.70 to 7.16	1.83 0.62 to 6.41	1.75 0.64 to 5.73	1.72 0.60 to 5.72	1.71 0.49 to 6.96	1.68 0.27 to 10.43	1.65 0.11 to 18.16	1.61 0.48 to 5.95	1.44 0.34 to 6.26	1.42 0.49 to 4.82	1.34 0.48 to 4.51	1.24 0.14 to 11.17	1.21 0.08 to 12.21	1.03 0.25 to 4.68	1.03 0.35 to 3.59	RETA_SC	0.95 0.32 to 3.23	0.92 0.09 to 8.28	0.88 0.26 to 3.54	0.85 0.16 to 5.04	0.75 0.02 to 20.80	0.66 0.19 to 2.59	0.58 0.05 to 4.79
ORFO_PO	3.43 2.52 to 4.81	52.23 5.50 to 1742	45.14 3.98 to 1703	22.47 1.33 to 1083	18.62 1.16 to 1106	16.16 4.24 to 93.14	14.62 2.59 to 159	13.62 0.53 to 885	11.62 3.37 to 40.74	10.12 4.16 to 28.41	7.78 2.92 to 22.52	7.68 2.00 to 35.96	7.16 4.37 to 11.88	6.64 3.08 to 15.07	6.64 2.42 to 20.32	6.21 2.84 to 13.68	5.42 0.71 to 67.77	4.81 2.71 to 8.75	4.05 1.34 to 12.82	3.11 1.16 to 8.83	2.67 1.33 to 5.49	2.54 0.41 to 10.91	2.52 0.57 to 9.10	2.30 0.92 to 5.91	2.19 1.27 to 3.76	2.14 1.34 to 3.47	1.95 1.21 to 3.19	1.86 1.28 to 2.71	1.82 1.23 to 2.73	1.80 0.85 to 3.97	1.77 0.39 to 7.32	1.70 0.14 to 14.20	1.69 0.87 to 3.23	1.53 0.55 to 3.89	1.50 1.06 to 2.14	1.43 0.93 to 2.17	1.30 0.18 to 8.45	1.26 0.11 to 9.45	1.10 0.38 to 2.86	1.09 0.64 to 1.86	1.06 0.31 to 3.08	ORFO_PO	0.98 0.11 to 6.60	0.94 0.43 to 1.99	0.89 0.22 to 3.59	0.78 0.02 to 19.04	0.69 0.31 to 1.47	0.63 0.07 to 3.54
VILDAGLIPTIN	3.52 0.54 to 30.14	58.35 2.69 to 2910	50.73 2.26 to 2765	24.38 0.75 to 1775	20.46 0.71 to 1767	16.85 1.77 to 243	16.06 1.17 to 352	15.25 0.30 to 1692	11.84 1.35 to 136	10.68 1.32 to 110	8.22 0.96 to 88.58	8.08 0.80 to 106	7.40 1.08 to 65.72	6.92 0.90 to 63.73	6.92 0.83 to 71.23	6.44 0.86 to 59.64	5.80 0.38 to 134	4.99 0.70 to 44.98	4.24 0.47 to 48.48	3.28 0.39 to 33.68	2.74 0.38 to 24.83	2.57 0.22 to 34.42	2.64 0.23 to 31.21	2.36 0.31 to 23.24	2.27 0.33 to 19.87	2.20 0.32 to 19.70	2.02 0.29 to 17.43	1.92 0.29 to 16.49	1.88 0.28 to 16.07	1.88 0.25 to 16.89	1.82 0.16 to 22.14	1.80 0.08 to 35.31	1.75 0.24 to 15.94	1.57 0.19 to 15.29	1.53 0.23 to 13.60	1.47 0.21 to 12.53	1.33 0.09 to 21.75	1.33 0.06 to 23.93	1.14 0.13 to 10.75	1.13 0.16 to 9.88	1.08 0.12 to 11.23	1.02 0.15 to 9.14	VILDAGLIPTIN	0.97 0.13 to 9.23	0.91 0.10 to 10.86	0.81 0.02 to 37.41	0.72 0.09 to 6.57	0.64 0.04 to 10.25
TASP_SC	3.66 1.86 to 7.46	56.20 5.24 to 1995	47.76 4.15 to 1873	24.09 1.35 to 1191	20.16 1.20 to 1171	17.57 3.92 to 105	15.63 2.48 to 189	14.67 0.51 to 936	12.35 3.12 to 49.06	10.80 3.79 to 35.69	8.28 2.73 to 28.34	8.07 1.97 to 41.54	7.69 3.48 to 16.52	7.09 2.76 to 19.23	7.08 2.19 to 25.91	6.58 2.44 to 17.95	5.79 0.68 to 78.02	5.14 2.42 to 11.18	4.34 1.24 to 15.48	3.34 1.05 to 11.26	2.86 1.11 to 7.15	2.69 0.41 to 12.92	2.69 0.53 to 11.08	2.45 0.80 to 7.72	2.32 1.08 to 5.00	2.27 1.11 to 4.72	2.07 1.12 to 3.90	1.98 0.96 to 4.12	1.94 0.95 to 3.99	1.92 0.74 to 5.38	1.86 0.38 to 8.84	1.83 0.14 to 17.12	1.81 0.75 to 4.29	1.63 0.49 to 4.80	1.60 0.77 to 3.41	1.53 0.73 to 3.21	1.39 0.19 to 9.46	1.35 0.11 to 10.91	1.18 0.34 to 3.71	1.15 0.52 to 2.58	1.14 0.28 to 3.82	1.07 0.50 to 2.34	1.03 0.11 to 7.83	TASP_SC	0.95 0.21 to 4.42	0.84 0.02 to 20.89	0.74 0.26 to 2.02	0.67 0.07 to 3.88
CANALIRA_SC	3.85 1.01 to 15.00	60.73 4.31 to 2463	51.51 3.33 to 2252	25.57 1.10 to 1389	21.93 0.91 to 1419	18.70 2.87 to 154	16.78 1.83 to 238	15.63 0.44 to 1169	13.04 2.28 to 75.90	11.67 2.24 to 59.98	8.84 1.73 to 46.69	8.57 1.29 to 63.25	8.04 2.02 to 32.31	7.51 1.66 to 35.26	7.48 1.47 to 41.86	6.89 1.56 to 32.09	6.19 0.56 to 105	5.40 1.34 to 22.34	4.50 0.82 to 25.73	3.54 0.69 to 18.08	2.99 0.69 to 13.31	2.81 0.31 to 20.95	2.83 0.38 to 18.19	2.61 0.52 to 12.60	2.44 0.61 to 10.35	2.42 0.62 to 9.50	2.19 0.54 to 8.83	2.09 0.54 to 8.08	2.04 0.54 to 7.86	2.03 0.53 to 7.98	1.98 0.27 to 13.52	1.95 0.11 to 23.66	1.90 0.44 to 8.14	1.71 0.32 to 8.72	1.68 0.42 to 6.72	1.61 0.41 to 6.08	1.45 0.14 to 14.22	1.44 0.08 to 15.19	1.23 0.24 to 6.17	1.22 0.30 to 4.96	1.18 0.20 to 6.39	1.13 0.28 to 4.46	1.10 0.09 to 10.10	1.05 0.23 to 4.87	CANALIRA_SC	0.88 0.02 to 27.35	0.79 0.16 to 3.56	0.71 0.06 to 6.01
INS_ASPART	4.43 0.18 to 140	75.38 1.43 to 8335	64.32 1.04 to 6654	31.56 0.40 to 4653	26.16 0.35 to 4649	21.62 0.66 to 942	20.34 0.54 to 1137	19.02 0.18 to 3585	14.89 0.54 to 520	13.26 0.53 to 466	10.12 0.40 to 363	9.96 0.35 to 397	9.07 0.39 to 292	8.64 0.34 to 286	8.59 0.34 to 289	7.84 0.32 to 275	7.20 0.18 to 444	6.18 0.25 to 194	5.21 0.19 to 181	4.04 0.16 to 141	3.40 0.14 to 111	3.22 0.09 to 136	3.18 0.11 to 124	2.91 0.12 to 96.60	2.79 0.12 to 88.36	2.72 0.11 to 86.30	2.48 0.11 to 81.53	2.39 0.10 to 74.27	2.33 0.10 to 73.33	2.31 0.09 to 78.80	2.28 0.07 to 86.12	2.21 0.04 to 124	2.20 0.09 to 70.95	1.95 0.07 to 67.45	1.92 0.08 to 63.16	1.83 0.08 to 56.73	1.69 0.04 to 80.54	1.63 0.03 to 85.60	1.36 0.05 to 46.26	1.35 0.06 to 46.18	1.34 0.05 to 48.74	1.29 0.05 to 41.00	1.24 0.03 to 64.31	1.19 0.05 to 40.30	1.14 0.04 to 45.00	INS_ASPART	0.89 0.04 to 28.71	0.79 0.02 to 39.45
LOTI_PO	4.93 2.48 to 10.76	77.10 7.40 to 2614	65.10 5.22 to 2497	33.14 1.78 to 1720	27.57 1.57 to 1621	24.02 5.20 to 151	21.28 3.37 to 260	19.48 0.68 to 1447	16.84 4.16 to 67.20	14.76 4.79 to 53.11	11.32 3.55 to 39.33	11.11 2.46 to 59.16	10.25 4.68 to 24.19	9.56 3.51 to 27.81	9.63 2.87 to 35.72	8.94 3.28 to 25.62	7.85 0.96 to 106	6.88 2.94 to 17.92	5.80 1.63 to 22.56	4.52 1.44 to 15.61	3.85 1.47 to 10.53	3.64 0.54 to 18.93	3.63 0.73 to 15.47	3.32 1.08 to 10.32	3.13 1.39 to 7.69	3.07 1.38 to 7.46	2.80 1.26 to 6.59	2.66 1.32 to 5.99	2.62 1.26 to 5.86	2.58 0.98 to 7.51	2.56 0.50 to 11.78	2.51 0.18 to 23.00	2.42 0.97 to 6.24	2.19 0.67 to 6.70	2.15 1.06 to 4.73	2.06 0.96 to 4.63	1.89 0.24 to 13.55	1.86 0.15 to 15.27	1.58 0.47 to 5.24	1.56 0.69 to 3.75	1.51 0.39 to 5.30	1.44 0.68 to 3.20	1.40 0.15 to 10.72	1.34 0.50 to 3.80	1.27 0.28 to 6.42	1.12 0.03 to 27.95	LOTI_PO	0.92 0.09 to 5.85
EXENIMP_IMPLANT	5.46 1.00 to 47.37	90.75 4.85 to 5402	77.48 3.73 to 4199	38.92 1.30 to 3018	32.38 1.17 to 2832	27.37 2.92 to 402	24.69 2.06 to 554	24.39 0.55 to 2514	18.74 2.22 to 218	16.67 2.55 to 177	12.45 1.85 to 131	12.47 1.45 to 169	11.36 1.99 to 102	10.65 1.63 to 107	10.68 1.61 to 111	9.92 1.58 to 96.32	8.84 0.60 to 246	7.68 1.32 to 73.35	6.49 0.87 to 75.96	5.05 0.71 to 50.42	4.28 0.70 to 40.17	3.98 0.38 to 55.52	4.05 0.41 to 46.07	3.68 0.53 to 38.13	3.46 0.61 to 31.26	3.35 0.62 to 30.64	3.06 0.59 to 26.75	2.94 0.54 to 25.71	2.88 0.53 to 26.41	2.86 0.46 to 27.64	2.83 0.30 to 34.93	2.73 0.13 to 56.98	2.71 0.44 to 24.96	2.41 0.33 to 24.57	2.38 0.42 to 21.21	2.27 0.40 to 19.96	2.10 0.16 to 33.32	2.00 0.10 to 38.42	1.73 0.23 to 17.98	1.72 0.31 to 15.40	1.72 0.21 to 18.22	1.59 0.28 to 13.96	1.56 0.10 to 26.90	1.49 0.26 to 13.80	1.41 0.17 to 17.59	1.26 0.03 to 52.70	1.09 0.17 to 11.12	EXENIMP_IMPLANT

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.169 (95% CrI 0.058 to 0.340), log scale
Residual deviance: 265.8 for 246 data points
DIC: 425.3 (pD 159.5)
Largest R-hat: 1.002
Smallest ESS: bulk 1,026, tail 1,700
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 111, treatment_policy 3
NoteRisk of bias, blinding: mixed: double_blind 65, not_reported 1, open_label 45, single_blind 3
NoteRisk of bias, funding: mixed: industry 107, mixed 3, non_industry 3, not_reported 1
NoteOutcome assessment, time point: selected time points span 4.43 to 365.26 weeks
NoteOutcome assessment, analysis set: mixed: completers 2, full_analysis 5, modified_itt 6, other 2, randomized 6, safety 93
NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, adverse event term hypoglycemia, threshold not stated 1, all cause deaths 1, all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period 1, Any signs or symptoms of hypoglycemia regardless of glucose 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, Grade 1 or 2 hypoglycemia below 3.9 mmol/L 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, hypoglycemia adverse event term, any severity 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia adverse reaction, undefined 1, Hypoglycemia preferred term, mostly mild by investigator 1, hypoglycemia reported as serious adverse event; level not stated 1, hypoglycemia requiring medical assistance 1, hypoglycemia, definition not stated 1, investigator reported symptomatic hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, not stated 85, participants with serious adverse events 1, plasma glucose 54 mg/dL or lower 1, serious adverse events 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia needing assistance of another person 1, severe hypoglycemia needing third party assistance 1, severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, TEAE leading to death 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 112, yes 2
NoteOutcome assessment, proportion method: mixed: not stated 111, observed 3
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 108, treatment_policy 1, while_on_treatment 5
NoteData handling, input conversions: arms_combined 59, count_from_percent 7, nonserious_only 121, printed_denominator 7

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT00960661	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT00935532	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	type 2 diabetes on biguanide with or without thiazolidinedione
NCT03555994	9	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT05407961	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out)
NCT00518115	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin
NCT01296412	26	safety	investigator reported symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
NCT00838916	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	56	safety	not stated	not stated	yes	not stated	while_on_treatment	not stated	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
PIONEER 4	57	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
REWIND	365.26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
NCT01476475	24	safety	Documented symptomatic, plasma glucose 3.9 mmol/L or lower	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
NCT01001104	12	safety	all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
AWARD-7	52	safety	Hypoglycaemia reported as treatment emergent adverse event	not stated	not stated	not stated	treatment_policy	treatment_policy	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT03235050	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin
NCT01175473	4.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more
SUSTAIN™ 3	62	safety	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2013	age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
NCT00393718	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 percent NGSP; with or without prior oral agents
EGO	16	safety	serious adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	overweight or obese adults with type 2 diabetes
NCT00765817	30	full_analysis	minor: symptoms with glucose below 3 mmol/L, self treated or resolved	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT01029886	26	modified_itt	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
SUSTAIN 7	45	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background
NCT00791479	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with type 2 diabetes on no background glucose lowering drug
NCT00637273	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin
SURPASS-1	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days
NCT00717457	104	safety	adverse event term hypoglycemia, threshold not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD
ACHIEVE-3	57	safety	hypoglycemia reported as serious adverse event; level not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	adults T2D on metformin; HbA1c 7.0 to 10.5 percent
NCT05579977	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
COMBINE 1	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults 18+; HbA1c 7.0-10.0%; BMI 40 or less; basal insulin 20-80 U/day; eGFR 30 or more
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
GETGOAL-L-ASIA	24	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT04867785	40	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 25 to 50; diet and exercise or stable metformin
GETGOAL-S	120	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
NCT06589765	52	safety	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
SUSTAIN 10	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	adults with T2D, HbA1c 7.0 to 11.0 percent on 1 to 3 oral drugs
NCT03951753	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT02229383	38	safety	minor: symptomatic, glucose below 3.0 mmol/L, not major	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT00577824	24	full_analysis	Any signs or symptoms of hypoglycemia regardless of glucose	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
ATTAIN-2	74	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes; BMI 27 or higher; HbA1c 7.0 to 10.0 percent
NCT02973321	26.4	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with type 2 diabetes and overweight or obesity
NCT01149421	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT01558271	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT00395746	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea
NCT01147627	48	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2010	newly diagnosed drug naive T2D; age 30 to 70; HbA1c 7 to 10 percent; BMI 20 to 35
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™1	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
NCT04093752	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without sulfonylurea
NCT00135330	20	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2005	age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only
LIRA-Ramadan™	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
ACHIEVE-5	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with T2D on insulin glargine with or without metformin or SGLT2 inhibitor
NCT00894322	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	industry	2009	adults with T2D on diet and exercise, metformin, TZD or both
AWARD-CHN1	30.29	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
NCT01733758	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout
AWARD-2	78	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	type 2 diabetes on metformin and glimepiride
NCT05514535	45	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-6	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
NCT01191268	56	safety	participants with serious adverse events	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults with type 2 diabetes on conventional insulin with or without metformin
NCT00375492	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	type 2 diabetes; weight loss trial
SURPASS-4	104.36	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents
NCT01003184	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
AWARD-CHN2	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT02324842	17.38	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	T2DM, HbA1c 7 to 11 percent, eGFR 60 or more, drug naive or metformin with or without SU
NCT00917267	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs
GETGOAL-X	116	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
SUSTAIN™	62	safety	severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
NCT01620489	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	type 2 diabetes; eGFR 30 to 59 mL/min/1.73m2 (MDRD); oral drugs and/or insulin
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
GETGOAL-F1	112	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
SURPASS-5	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin
NCT03322631	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
NCT00641056	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea
ELEGANT	26	randomized	Grade 1 or 2 hypoglycemia below 3.9 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT01126580	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
PIONEER 11	31	safety	ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
NCT01272232	68	safety	hypoglycemia adverse event term, any severity	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs
NCT00943917	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 to 70; HbA1c 7 to 10 percent; BMI 40 or less; stable metformin 3 months
SUSTAIN 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated
NCT00382239	12	full_analysis	Hypoglycemia preferred term, mostly mild by investigator	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
SUSTAIN™ 6	109	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor
SURPASS-SWITCH	44	safety	all cause deaths	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg
PIONEER 9	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 y or older; HbA1c 6.5 to 9.5 on one oral drug washed out, or 7.0 to 10.0 on diet and exercise
ACHIEVE-1	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes on diet and exercise alone; HbA1c 7.0 to 9.5 percent
DUAL™ I Japan	53	safety	severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2015	Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug
NCT00676338	26	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
LIXILAN JP-O1	52.43	safety	TEAE leading to death	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
PIONEER 5	31	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	type 2 diabetes; HbA1c 7.0 to 9.5 percent; moderate renal impairment
DUAL™ II Japan	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
LEAD-5	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
NCT04998032	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
AWARD-1	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults with type 2 diabetes on metformin and pioglitazone
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT05048719	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	adults with type 2 diabetes, HbA1c 7.0 to 10.5 percent, BMI 23 or more, diet or metformin
NCT00700817	52	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
PIONEER 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults with type 2 diabetes on basal, premixed or basal bolus insulin with or without metformin
S002858	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry		T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002904	12	full_analysis	hypoglycemia, definition not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2014	age 20 or older; HbA1c 8.0 percent or more; diet or oral drugs; no insulin or GLP-1 RA
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S002947	25	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S002969	52.14	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 70; BMI 30 to 50; HbA1c 48 to below 97 mmol/mol; T2DM under 10 years; undergoing LAGB
NCT05654831	4.86	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	MAD: age 18 to 70; BMI 24 to 40; HbA1c 7.0 to 10.5 percent; T2DM on metformin or lifestyle
S002991	13.04	other	hypoglycemia adverse reaction, undefined	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2023	age 65 or older; newly diagnosed T2D; UACR 30 to 300 mg/g; eGFR 60 to 90
S003058	12	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry		age 20 to 90; HbA1c 7.0 to 10.0 percent; on insulin glargine plus sitagliptin 50 mg at least 8 weeks
S003072	14	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2011	age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	0 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	11 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	3 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	24 / 388	arms_combined	R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	3 / 185		R0022521:Table 2
NCT05407961	A1	OTHER_ACTIVE_macupatide	12	arm, events	0 / 15		R0015193:Table 2
NCT05407961	A2	DULA_SC	12	arm, events	3 / 29		R0015193:Table 2
NCT05407961	A3	DULAMACU_SC	12	arm, events	1 / 28		R0015193:Table 2
NCT00518115	A1	PLACEBO	24	arm, events	0 / 52	nonserious_only	registry:adverse_events
NCT00518115	A10+A3+A4+A5+A6+A7+A8+A9	ALBI_SC	24	arm, events	10 / 274	nonserious_only;arms_combined	registry:adverse_events
NCT00518115	A2	EXEN_SC	24	arm, events	2 / 35	nonserious_only	registry:adverse_events
NCT01296412	A1	SITAGLIPTIN	26	arm, events	4 / 326		R0026295:Table 3
NCT01296412	A2	LIRA_SC	26	arm, events	6 / 327		R0026295:Table 3
NCT00838916	A1	ALBI_SC	164	arm, events	29 / 516	nonserious_only	registry:adverse_events
NCT00838916	A2	INS_GLARGINE	164	arm, events	4 / 263	nonserious_only	registry:adverse_events
SURPASS-6	A1+A2+A3	TIRZ_SC	56	arm, events	28 / 717	arms_combined	R0009666:Table 3
SURPASS-6	A4	INS_LISPRO	56	arm, events	4 / 711		R0009666:Table 3
PIONEER 4	A1	SEMA_PO	57	arm, events	22 / 285		R0015836:Table 3
PIONEER 4	A2	LIRA_SC	57	arm, events	11 / 284		R0015836:Table 3
PIONEER 4	A3	PLACEBO	57	arm, events	4 / 142		R0015836:Table 3
REWIND	A1	PLACEBO	365.26	arm, events	208 / 4,952	nonserious_only	registry:adverse_events
REWIND	A2	DULA_SC	365.26	arm, events	361 / 4,949	nonserious_only	registry:adverse_events
COMBINE 2	A1	ICOSEMA_SC	57	arm, events	11 / 342		R0005851:Table 4
COMBINE 2	A2	SEMA_SC	57	arm, events	17 / 341		R0005851:Table 4
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	28 / 198		R0024063:Table 3
SCALE™ Insulin	A2	PLACEBO	58	arm, events	17 / 198		R0024063:Table 3
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	3 / 161		R0021236:Table 2
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:Table 2
NCT01001104	A1	PLACEBO	12	arm, events	0 / 37		R0015000:Table 3
NCT01001104	A2+A3+A4	DULA_SC	12	arm, events	3 / 108	arms_combined	R0015000:Table 3
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	48 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	57	arm, events	6 / 65		R0018421:Table 2
AWARD-7	A1	INS_GLARGINE	52	arm, events	6 / 194		R0017387:Table 2
AWARD-7	A2+A3	DULA_SC	52	arm, events	22 / 383	arms_combined	R0017387:Table 2
NCT01584232	A1	DULA_SC	26	arm, events	16 / 181		R0016159:Table 3
NCT01584232	A2	INS_GLARGINE	26	arm, events	6 / 180		R0016159:Table 3
NCT03235050	A1	PLACEBO	58	arm, events	2 / 112	nonserious_only	registry:adverse_events
NCT03235050	A2	LIRA_SC	58	arm, events	2 / 110	nonserious_only	registry:adverse_events
NCT03235050	A3+A4+A5	COTA_SC	58	arm, events	24 / 612	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™ 3	A1	SEMA_SC	62	arm, events	26 / 406	nonserious_only	registry:adverse_events
SUSTAIN™ 3	A2	EXENER_SC	62	arm, events	21 / 407	nonserious_only	registry:adverse_events
NCT00393718	A1	LIRA_SC	52	arm, events	22 / 272		R0022766:Table 4
NCT00393718	A2	GLIBENCLAMIDE	52	arm, events	7 / 139		R0022766:Table 4
EGO	A1+A2+A3	DULA_SC	16	arm, events	15 / 196	nonserious_only;arms_combined	registry:adverse_events
EGO	A4	PLACEBO	16	arm, events	0 / 66	nonserious_only	registry:adverse_events
NCT00765817	A1	EXEN_SC	30	arm, events	14 / 138		R0027069:Table 3
NCT00765817	A2	PLACEBO	30	arm, events	2 / 123		R0027069:Table 3
NCT01029886	A1	EXENER_SC	26	arm, events	21 / 461		R0016299:Table 3
NCT01029886	A2	LIRA_SC	26	arm, events	22 / 451		R0016299:Table 3
SUSTAIN 7	A1+A2	SEMA_SC	45	arm, events	30 / 601	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN 7	A3+A4	DULA_SC	45	arm, events	25 / 600	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A1+A2+A3+A4+A5	DULA_SC	12	arm, events	7 / 135	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A6	PLACEBO	12	arm, events	1 / 32	nonserious_only	registry:adverse_events
NCT00637273	A1	EXENER_SC	26	arm, events	10 / 170	count_from_percent	R0024240:Table 4
NCT00637273	A2	SITAGLIPTIN	26	arm, events	3 / 172	count_from_percent	R0024240:Table 4
NCT00637273	A3	PIOGLITAZONE	26	arm, events	2 / 172	count_from_percent	R0024240:Table 4
SURPASS-1	A1+A2+A3	TIRZ_SC	44	arm, events	21 / 363	nonserious_only;arms_combined	registry:adverse_events
SURPASS-1	A4	PLACEBO	44	arm, events	1 / 115	nonserious_only	registry:adverse_events
NCT00717457	A1+A2	TASP_SC	104	arm, events	64 / 797	arms_combined	R0013639:Table 2
NCT00717457	A3	EXEN_SC	104	arm, events	14 / 392		R0013639:Table 2
ACHIEVE-3	A1+A2	ORFO_PO	57	arm, events	111 / 847	nonserious_only;arms_combined	registry:adverse_events
ACHIEVE-3	A3+A4	SEMA_PO	57	arm, events	71 / 851	nonserious_only;arms_combined	registry:adverse_events
NCT05579977	A1+A8	PLACEBO	28	arm, events	6 / 139	arms_combined	R0004106:Table 2
NCT05579977	A10+A11+A12+A13+A2+A3+A4+A5+A6+A9	LOTI_PO	28	arm, events	106 / 690	arms_combined	R0004106:Table 2
NCT05579977	A7	SEMA_PO	28	arm, events	4 / 73		R0004106:Table 2
COMBINE 1	A1	ICOSEMA_SC	57	arm, events	39 / 646	nonserious_only	registry:adverse_events
COMBINE 1	A2	INS_ICODEC	57	arm, events	8 / 645	nonserious_only	registry:adverse_events
SUSTAIN 9	A1	SEMA_SC	36	arm, events	10 / 151	nonserious_only	registry:adverse_events
SUSTAIN 9	A2	PLACEBO	36	arm, events	0 / 151	nonserious_only	registry:adverse_events
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	8 / 154		R0022626:Table 2
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	4 / 157		R0022626:Table 2
NCT04867785	A1	PLACEBO	40	arm, events	1 / 45	nonserious_only	registry:adverse_events
NCT04867785	A2	DULA_SC	40	arm, events	3 / 46	nonserious_only	registry:adverse_events
NCT04867785	A3+A4+A5+A6+A7+A8	RETA_SC	40	arm, events	19 / 190	nonserious_only;arms_combined	registry:adverse_events
GETGOAL-S	A1	PLACEBO	120	arm, events	11 / 286	nonserious_only	registry:adverse_events
GETGOAL-S	A2	LIXI_SC	120	arm, events	30 / 573	nonserious_only	registry:adverse_events
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	30 / 608	count_from_percent;arms_combined	R0029347:Extended Data Figure 5
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	8 / 202	count_from_percent	R0029347:Extended Data Figure 5
SUSTAIN 10	A1	SEMA_SC	35	arm, events	17 / 290	nonserious_only	registry:adverse_events
SUSTAIN 10	A2	LIRA_SC	35	arm, events	10 / 287	nonserious_only	registry:adverse_events
NCT01175473	A1	LIXI_SC	4.43	arm, events	2 / 77	nonserious_only	registry:adverse_events
NCT01175473	A2	LIRA_SC	4.43	arm, events	5 / 71	nonserious_only	registry:adverse_events
NCT03951753	A1	TIRZ_SC	32	arm, events	6 / 45	nonserious_only	registry:adverse_events
NCT03951753	A2	SEMA_SC	32	arm, events	8 / 44	nonserious_only	registry:adverse_events
NCT03951753	A3	PLACEBO	32	arm, events	0 / 28	nonserious_only	registry:adverse_events
NCT00960661	A1	EXEN_SC	30	arm, events	7 / 316	nonserious_only	registry:adverse_events
NCT00960661	A2	INS_LISPRO	30	arm, events	2 / 321	nonserious_only	registry:adverse_events
NCT00935532	A1	EXENER_SC	26	arm, events	24 / 215	nonserious_only	registry:adverse_events
NCT00935532	A2	INS_GLARGINE	26	arm, events	7 / 212	nonserious_only	registry:adverse_events
NCT03555994	A1	PLACEBO	9	arm, events	0 / 11		R0005744:Table 2
NCT03555994	A2	LIRA_SC	9	arm, events	2 / 10		R0005744:Table 2
NCT03555994	A3	COTA_SC	9	arm, events	2 / 9		R0005744:Table 2
NCT02229383	A1	EXENER_SC	38	arm, events	2 / 233		R0014763:Table 3
NCT02229383	A2	PLACEBO	38	arm, events	4 / 231		R0014763:Table 3
NCT00577824	A1	PLACEBO	24	arm, events	1 / 36		R0018881:Table 2
NCT00577824	A2+A3	EXEN_SC	24	arm, events	21 / 145	arms_combined	R0018881:Table 2
ATTAIN-2	A1	PLACEBO	74	arm, events	49 / 630	nonserious_only	registry:adverse_events
ATTAIN-2	A2+A3+A4	ORFO_PO	74	arm, events	200 / 983	nonserious_only;arms_combined	registry:adverse_events
NCT02973321	A1	PLACEBO	26.4	arm, events	1 / 33	nonserious_only	registry:adverse_events
NCT02973321	A5	LIRA_SC	26.4	arm, events	2 / 67	nonserious_only	registry:adverse_events
NCT01149421	A1+A2	DULA_SC	26	arm, events	20 / 505	nonserious_only;arms_combined	registry:adverse_events
NCT01149421	A3	PLACEBO	26	arm, events	2 / 250	nonserious_only	registry:adverse_events
NCT01558271	A1	DULA_SC	52	arm, events	22 / 281		R0011754:Table 2
NCT01558271	A2	LIRA_SC	52	arm, events	11 / 141		R0011754:Table 2
NCT00849017	A1	PLACEBO	164	arm, events	4 / 105	nonserious_only	registry:adverse_events
NCT00849017	A2+A3	ALBI_SC	164	arm, events	9 / 204	nonserious_only;arms_combined	registry:adverse_events
NCT00395746	A1+A2	LIRA_SC	52	arm, events	19 / 178	nonserious_only;arms_combined	registry:adverse_events
NCT00395746	A3	PLACEBO	52	arm, events	4 / 89	nonserious_only	registry:adverse_events
NCT01147627	A1	EXEN_SC	48	arm, events	6 / 142	nonserious_only	registry:adverse_events
NCT01147627	A2	INS_PREMIX	48	arm, events	0 / 138	nonserious_only	registry:adverse_events
NCT01147627	A3	PIOGLITAZONE	48	arm, events	1 / 136	nonserious_only	registry:adverse_events
NCT05759897	A1	PLACEBO	16	arm, events	0 / 39	printed_denominator	R0002101:Supplement eTable 6
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	5 / 155	printed_denominator;arms_combined	R0002101:Supplement eTable 6
SUSTAIN™1	A1+A2	SEMA_SC	35	arm, events	13 / 259	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™1	A3	PLACEBO	35	arm, events	1 / 129	nonserious_only	registry:adverse_events
NCT04093752	A1+A2+A3	TIRZ_SC	44	arm, events	52 / 687	nonserious_only;arms_combined	registry:adverse_events
NCT04093752	A4	INS_GLARGINE	44	arm, events	3 / 230	nonserious_only	registry:adverse_events
NCT00135330	A1	EXEN_SC	20	arm, events	2 / 45	nonserious_only	registry:adverse_events
NCT00135330	A2	EXENROSI_SC	20	arm, events	3 / 47	nonserious_only	registry:adverse_events
NCT00135330	A3	ROSIGLITAZONE	20	arm, events	0 / 45	nonserious_only	registry:adverse_events
LIRA-Ramadan™	A1	LIRA_SC	30	arm, events	8 / 172		R0025756:Supplement Table S2
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	1 / 171		R0025756:Supplement Table S2
NCT02200991	A1	LIXI_SC	4.43	arm, events	3 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Table 3
ACHIEVE-5	A1	PLACEBO	42	arm, events	6 / 141	nonserious_only	registry:adverse_events
ACHIEVE-5	A2+A3+A4	ORFO_PO	42	arm, events	45 / 405	nonserious_only;arms_combined	registry:adverse_events
NCT00894322	A1	EXENER_SC	12	arm, events	1 / 23	nonserious_only	registry:adverse_events
NCT00894322	A2	PLACEBO	12	arm, events	0 / 12	nonserious_only	registry:adverse_events
AWARD-CHN1	A1+A2	DULA_SC	30.29	arm, events	15 / 492	nonserious_only;arms_combined	registry:adverse_events
AWARD-CHN1	A3	GLIMEPIRIDE	30.29	arm, events	0 / 245	nonserious_only	registry:adverse_events
NCT01733758	A2+A3	ALBI_SC	52	arm, events	31 / 310	printed_denominator;arms_combined	R0010997:Table 3
NCT01733758	A4	LIRA_SC	52	arm, events	7 / 103	printed_denominator	R0010997:Table 3
AWARD-2	A1+A2	DULA_SC	78	arm, events	15 / 545	nonserious_only;arms_combined	registry:adverse_events
AWARD-2	A3	INS_GLARGINE	78	arm, events	3 / 265	nonserious_only	registry:adverse_events
NCT05514535	A1	SEMA_SC	45	arm, events	23 / 288	nonserious_only	registry:adverse_events
NCT05514535	A2	INS_GLARGINE	45	arm, events	0 / 285	nonserious_only	registry:adverse_events
AWARD-6	A1	DULA_SC	30	arm, events	11 / 299	nonserious_only	registry:adverse_events
AWARD-6	A2	LIRA_SC	30	arm, events	17 / 300	nonserious_only	registry:adverse_events
NCT01191268	A1+A2	DULA_SC	56	arm, events	18 / 588	nonserious_only;arms_combined	registry:adverse_events
NCT01191268	A3	INS_GLARGINE	56	arm, events	5 / 296	nonserious_only	registry:adverse_events
NCT00375492	A1	EXEN_SC	24	arm, events	9 / 96	nonserious_only	registry:adverse_events
NCT00375492	A2	PLACEBO	24	arm, events	10 / 98	nonserious_only	registry:adverse_events
SURPASS-4	A1+A2+A3	TIRZ_SC	104.36	arm, events	45 / 997	nonserious_only;arms_combined	registry:adverse_events
SURPASS-4	A4	INS_GLARGINE	104.36	arm, events	5 / 1,005	nonserious_only	registry:adverse_events
NCT01003184	A1	EXENER_SC	26	arm, events	10 / 111		R0027663:Table 2
NCT01003184	A2	INS_DETEMIR	26	arm, events	3 / 111		R0027663:Table 2
AWARD-CHN2	A1+A2	DULA_SC	56	arm, events	17 / 515	nonserious_only;arms_combined	registry:adverse_events
AWARD-CHN2	A3	INS_GLARGINE	56	arm, events	0 / 259	nonserious_only	registry:adverse_events
NCT02324842	A1	CANAGLIFLOZIN	17.38	arm, events	0 / 15	nonserious_only	registry:adverse_events
NCT02324842	A2	LIRA_SC	17.38	arm, events	5 / 15	nonserious_only	registry:adverse_events
NCT02324842	A3	CANALIRA_SC	17.38	arm, events	5 / 15	nonserious_only	registry:adverse_events
NCT00917267	A1	EXENER_SC	26	arm, events	20 / 340	printed_denominator	R0026895:Table 2
NCT00917267	A2	EXEN_SC	26	arm, events	24 / 338	printed_denominator	R0026895:Table 2
GETGOAL-X	A1	LIXI_SC	116	arm, events	14 / 320	nonserious_only	registry:adverse_events
GETGOAL-X	A2	EXEN_SC	116	arm, events	17 / 319	nonserious_only	registry:adverse_events
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	81 / 480	arms_combined	R0025024:Table 2
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	5 / 121		R0025024:Table 2
NCT01620489	A1	LIRA_SC	27	arm, events	8 / 140	nonserious_only	registry:adverse_events
NCT01620489	A2	PLACEBO	27	arm, events	2 / 139	nonserious_only	registry:adverse_events
NCT05486065	A1+A2+A3	SEMA_SC	49	arm, events	22 / 185	nonserious_only;arms_combined	registry:adverse_events
NCT05486065	A4	PLACEBO	49	arm, events	3 / 60	nonserious_only	registry:adverse_events
GETGOAL-F1	A1	PLACEBO	112	arm, events	3 / 160	nonserious_only;printed_denominator	registry:adverse_events
GETGOAL-F1	A2+A3	LIXI_SC	112	arm, events	13 / 322	nonserious_only;arms_combined	registry:adverse_events
SURPASS-5	A1+A2+A3	TIRZ_SC	44	arm, events	23 / 355	nonserious_only;arms_combined	registry:adverse_events
SURPASS-5	A4	PLACEBO	44	arm, events	2 / 120	nonserious_only	registry:adverse_events
NCT03322631	A1	PLACEBO	12	arm, events	1 / 9		R0021917:Table 2
NCT03322631	A2+A3+A4	TIRZ_SC	12	arm, events	16 / 39	arms_combined	R0021917:Table 2
NCT00641056	A1	EXENER_SC	26	arm, events	7 / 233	count_from_percent	R0024240:Table 4
NCT00641056	A2	INS_GLARGINE	26	arm, events	4 / 234	count_from_percent	R0024240:Table 4
ELEGANT	A1	LIRA_SC	26	arm, events	14 / 26		R0025175:Table 3
ELEGANT	A2	STANDARD_CARE	26	arm, events	2 / 24		R0025175:Table 3
NCT01126580	A1+A2	DULA_SC	52	arm, events	30 / 539	nonserious_only;arms_combined	registry:adverse_events
NCT01126580	A3	METFORMIN	52	arm, events	3 / 268	nonserious_only	registry:adverse_events
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	11 / 390	arms_combined	R0019663:Table 3
PIONEER 11	A4	PLACEBO	31	arm, events	0 / 131		R0019663:Table 3
NCT01272232	A1+A2	LIRA_SC	68	arm, events	88 / 634	nonserious_only;arms_combined	registry:adverse_events
NCT01272232	A3	PLACEBO	68	arm, events	13 / 212	nonserious_only	registry:adverse_events
NCT00943917	A1+A2	EXENIMP_IMPLANT	12	arm, events	7 / 102	nonserious_only;arms_combined	registry:adverse_events
NCT00943917	A3	EXEN_SC	12	arm, events	1 / 53	nonserious_only	registry:adverse_events
SUSTAIN 8	A1	SEMA_SC	57	arm, events	20 / 394	nonserious_only	registry:adverse_events
SUSTAIN 8	A2	CANAGLIFLOZIN	57	arm, events	23 / 394	nonserious_only	registry:adverse_events
NCT00382239	A1	PLACEBO	12	arm, events	2 / 40		R0027621:Table 3
NCT00382239	A2+A3+A4	EXEN_SC	12	arm, events	11 / 113	arms_combined	R0027621:Table 3
SUSTAIN™ 6	A1+A2	SEMA_SC	109	arm, events	125 / 1,648	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™ 6	A3+A4	PLACEBO	109	arm, events	73 / 1,649	nonserious_only;arms_combined	registry:adverse_events
SURPASS-SWITCH	A1	TIRZ_SC	44	arm, events	12 / 139	nonserious_only	registry:adverse_events
SURPASS-SWITCH	A2	DULA_SC	44	arm, events	11 / 143	nonserious_only	registry:adverse_events
PIONEER 9	A1+A2+A3	SEMA_PO	57	arm, events	17 / 146	nonserious_only;arms_combined	registry:adverse_events
PIONEER 9	A4	LIRA_SC	57	arm, events	9 / 48	nonserious_only	registry:adverse_events
PIONEER 9	A5	PLACEBO	57	arm, events	3 / 49	nonserious_only	registry:adverse_events
ACHIEVE-1	A1	PLACEBO	42	arm, events	5 / 138	nonserious_only	registry:adverse_events
ACHIEVE-1	A2+A3+A4	ORFO_PO	42	arm, events	55 / 421	nonserious_only;arms_combined	registry:adverse_events
DUAL™ I Japan	A1	IDEGLIRA_SC	53	arm, events	27 / 275		R0014857:Table 2
DUAL™ I Japan	A2	INS_DEGLUDEC	53	arm, events	12 / 271		R0014857:Table 2
DUAL™ I Japan	A3	LIRA_SC	53	arm, events	38 / 273		R0014857:Table 2
NCT00676338	A1	EXENER_SC	26	arm, events	21 / 248		R0027761:Table 1
NCT00676338	A2	METFORMIN	26	arm, events	8 / 246		R0027761:Table 1
NCT00676338	A3	PIOGLITAZONE	26	arm, events	3 / 163		R0027761:Table 1
NCT00676338	A4	SITAGLIPTIN	26	arm, events	4 / 163		R0027761:Table 1
NCT05086445	A1	PLACEBO	14	arm, events	1 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	10 / 49	arms_combined	R0003844:Table 2
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.43	arm, events	4 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.43	arm, events	10 / 160		R0015751:Table 3
PIONEER 5	A1	SEMA_PO	31	arm, events	19 / 163	nonserious_only	registry:adverse_events
PIONEER 5	A2	PLACEBO	31	arm, events	6 / 161	nonserious_only	registry:adverse_events
DUAL™ II Japan	A1	IDEGLIRA_SC	27	arm, events	9 / 105		R0015589:Table 2
DUAL™ II Japan	A2	INS_DEGLUDEC	27	arm, events	4 / 105		R0015589:Table 2
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	39 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	6 / 102		R0007136:Table 2
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	27 / 205	arms_combined	R0014736:Supplement Table S4
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	4 / 103		R0014736:Supplement Table S4
LEAD-5	A1	LIRA_SC	27	arm, events	5 / 232		R0027336:Supplement Table 2
LEAD-5	A3	INS_GLARGINE	27	arm, events	2 / 234		R0027336:Supplement Table 2
NCT04998032	A1	EFSUBA_SC	24	arm, events	6 / 171		R0006975:Table 3
NCT04998032	A2	PLACEBO	24	arm, events	3 / 173		R0006975:Table 3
AWARD-1	A1+A2	DULA_SC	56	arm, events	21 / 559	nonserious_only;arms_combined	registry:adverse_events
AWARD-1	A3	EXEN_SC	56	arm, events	5 / 278	nonserious_only	registry:adverse_events
NCT03311724	A1	PLACEBO	16	arm, events	0 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	9 / 85	arms_combined	R0010282:Table 2
NCT05048719	A1	PLACEBO	28	arm, events	1 / 55	nonserious_only	registry:adverse_events
NCT05048719	A2+A3+A4+A5+A6+A7+A8	ORFO_PO	28	arm, events	32 / 278	nonserious_only;arms_combined	registry:adverse_events
NCT05048719	A9	DULA_SC	28	arm, events	0 / 50	nonserious_only	registry:adverse_events
NCT00700817	A1+A2	LIRA_SC	52	arm, events	23 / 446	arms_combined	R0024199:Table 2
NCT00700817	A3	SITAGLIPTIN	52	arm, events	8 / 219		R0024199:Table 2
PIONEER 8	A1+A2+A3	SEMA_PO	57	arm, events	35 / 547	nonserious_only;arms_combined	registry:adverse_events
PIONEER 8	A4	PLACEBO	57	arm, events	5 / 184	nonserious_only	registry:adverse_events
S002858	A1	LIXI_SC	24	arm, events	2 / 51		R0001573:Supplement Table S1
S002858	A2	PLACEBO	24	arm, events	1 / 50		R0001573:Supplement Table S1
S002904	A1	LIRAGL_SC	12	arm, events	0 / 60		R0003210:Table 3
S002904	A2	LIRA_SC	12	arm, events	1 / 60		R0003210:Table 3
S002946	A1	SEMA_SC	26	arm, events	4 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC	26	arm, events	2 / 16		R0006360:Supplement Table S2
S002947	A1+A2+A3	ECNO_SC	25	arm, events	8 / 109	arms_combined	R0006482:Table 3
S002947	A4	PLACEBO	25	arm, events	2 / 36		R0006482:Table 3
S002969	A1	LIRA_SC	52.14	arm, events	1 / 13		R0010852:Table 3
S002969	A2	PLACEBO	52.14	arm, events	0 / 14		R0010852:Table 3
NCT05654831	A1+A2+A3+A4	ECC500_PO	4.86	arm, events	11 / 39	arms_combined	R0007796:Table 2
NCT05654831	A5	PLACEBO	4.86	arm, events	3 / 13		R0007796:Table 2
S002991	A1	SEMA_SC	13.04	arm, events	0 / 110		R0009861:Results
S002991	A2	INS_ASPART	13.04	arm, events	1 / 110		R0009861:Results
S003058	A1	LIXI_SC	12	arm, events	0 / 23		R0024376:Results
S003058	A2	VILDAGLIPTIN	12	arm, events	1 / 25		R0024376:Results
S003072	A1	VILDAGLIPTIN	14	arm, events	2 / 62		R0023470:Table 4
S003072	A2	LIRA_SC	14	arm, events	1 / 60		R0023470:Table 4
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab